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The divergence of the two superfamilies belonging to the Infraorder Catarrhini – 
Cercopithecoidea (Old World monkeys) and Hominoidea (apes, including 
humans) – is generally assumed to have occurred during the Oligocene, between 
38 and 20 million years ago.  Genetic studies indicate that this time period was 
one of active genetic evolution under strong purifying selection for catarrhine 
primates.  This includes selective pressures on the glycoprotein 
galactosyltransferase 1 (GGTA1) gene and subsequent inactivation “clocked” at 
approximately 28 ma, possibly prior to the Cercopithecoidea/Hominoidea split.  
The GGTA1 gene codes for an α1,3 galactosyltransferase (GT) enzyme that 
synthesizes a terminal disaccharide, αgalactosyl (αGal), found on glycoproteins 
and glycolipids on the surface of cells in the tissues of most mammals.  Currently, 
catarrhines are the only mammals studied for the terminal αGal residue that do not 
express this sugar on their cell surfaces.  The proposed selective advantage of this 
mutation for catarrhines is the ability to produce anti-Gal antibodies, which may 
 
be an effective immune component in neutralizing αGal-expressing pathogens, as 
certain helminthes, many bacteria, including those found in primate guts, and 
some viruses derived from GGTA1 positive species express αGal on their 
surfaces.  However, many viruses are known to utilize host cell carbohydrates in 
various ways such as binding receptors or attachment proteins, making these 
moieties “hot spots” for selective evolution.  Cell surface αGal may have 
predisposed ancestral catarrhines to pathogens and toxins that could utilize the 
terminal sugar moieties on host cells as binding sites or in other capacities during 
infection.  I found that, in fact, the presence or absence of cell surface αGal 
affects the course of certain viral infections.  Infections of paired cell lines with 
differential expression of GT showed that Sindbis viruses (SINV) preferentially 
replicate in αGal-positive cells, whereas herpes simplex viruses type 1 and type 2 
(HSV-1 and HSV-2) preferentially grow in cells lacking αGal.  In both cases, 
differences in infection levels resulted from the ability of the virus to successfully 
initiate infection.  This points to a role for αGal in the early stages of viral 
infections.  I also showed that GT knockout mice infected with HSV-2 had higher 
viral load and greater pathology compared to WT B6 mice that naturally express 
αGal.  The increased susceptibility of KO mice to HSV-2 was not due to an 
immune component as differences in viral load and pathology were even more 
evident in immunocompromised mice.  This clearly indicates that αGal expression 
in cells or animal hosts can affect the course of viral infections.  I was not able to 
further confirm differences in susceptibility to HSV 1 and 2 using mouse 
backcrosses (KO x WT).  Unknown genetic factors, that are independent of αGal 
 
expression, may be introduced during the crosses that need to be further 
investigated.  Infections of KO and WT mice with other herpes viruses did not 
yield definitive data and require further studies with suitable reagents.  The 
mechanism by which GT-dependent differential susceptibility to viruses operates 
still remains to be deciphered.  However, it is clear that susceptibility to certain 
viral infections is tied to the presence or absence of αGal on the surface of host 
cells.  Overall, these results have implications for the evolution of resistance to 
viral infections in catarrhines.  Pathogens exert great selective pressure on their 
hosts, and it is possible that a pathogen, able to exploit αGal, could have helped 
shape primate lineage evolution during the Oligocene. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Catarrhine evolution and the glycoprotein, glycosyltransferase gene 1 
(GGTA1) locus 
The phylogenetic split of the two superfamilies belonging to the infraorder 
Catarrhini – Cercopithecoidea (Old World monkeys; OWM) and Hominoidea 
(apes, including humans) – occurred during the Oligocene, estimated at about 29 
Ma (Steiper et al., 2004; Chatterjee et al., 2009; Zalmout et al., 2010).  More 
conservative estimates, primarily based on fossil evidence, place the OWM and 
ape divergence sometime between 38-20 Ma, essentially bracketing the entire 
Oligocene (Raaum et al., 2005; Stewart and Disotell, 1998; Steiper and Young, 
2008; Perelman et al., 2011; Pozzi et al., 2011). Molecular studies indicate that 
the early part of the Oligocene epoch (~35.0-23.0 Ma) was a period of active 
genetic evolution under strong purifying selection for catarrhines (Galili et al., 
1991; Koike et al., 2007).  This may have included a mutation on the glycoprotein 
galactosyltransferase 1 (GGTA1) locus.  Catarrhini are unique among mammals 
because a loss-of function mutation, which has been molecularly clocked at 
approximately 28.1 million years ago, resulted in the inactivation of the GGTA1 
gene (Figure 1) (Koike et al., 2007).  In animals with an active GGTA1, the gene 
codes for the α1,3 galactosyltransferase (α1,3GT or GT) enzyme, which is 
responsible for the addition of the terminal galactosyl unit to αGal 
(Galα1,3Galβ1,4GlcNAc-R) carbohydrate chains found on cell surface 

glycoproteins and glycolipids in the tissues of most mammals (Galili et al., 1985; 
Galili et al., 1987; Galili et al., 1988).  Due to loss of GT expression, OWM and 
apes do not express the cell surface carbohydrate, αGal (Galili and Swanson, 
1991; Koike et al., 2002).  All other extant primates – Platyrrhini (New World 
monkeys (NWM)) and Strepsirrhini (lemurs and lorises) (Galili et al., 1988; Galili 
and Swanson, 1991) — retain an actively expressed α1,3GT gene and therefore 
have enzymatic activity that catalyzes production of the terminal galactose sugar.   
Figure 1: Primate phylogeny on the geological time scale.  The Hominoidea and 
Cercopithecoidea lineages diverged during the Oligocene, some time after 28.1 Ma 
when the GGTA1 gene was inactivated.  The shaded area highlights the primate 
lineages lacking αGal expression. 
 
The significance of GGTA1 inactivation is of interest to studies in primate 
evolution for several reasons: (1) inactivation occurred during the Oligocene 
epoch, a period of ambiguity in catarrhine evolutionary history; (2) inactivation 
occurred in relatively few taxa in the Order Primates, but active expression is 
conserved across the vast majority of Class Mammalia, and of most importance 
for this dissertation; (3) suppression of αGal expression in catarrhines has been 
associated with a selective advantage against pathogenic agents. 
 
1.2 Primate biogeography and biodiversity at the Eocene-Oligocene 
transition 
The Grande Coupure at the Eocene-Oligocene boundary is characterized by a 
shift in global climate commonly referred to as “greenhouse to icehouse” 
(Prothero 1994; Seiffert, 2007; Pearson et al., 2008; Maravelis and Zelilidis 
2012).  Cool conditions and pronounced seasonality continued for most of the 
epoch until the onset of warmer climate approximately 25 Ma.  The transition 
from the late Eocene into the late Oligocene is also marked by a massive turnover 
of marine biota as well as terrestrial fauna and flora (Prothero 1994; Kappelman 
et al., 2003; Pearson et al., 2008; Figueirido et al., 2012; Maravelis and Zelilidis 
2012; Wade et al., 2012).  Terrestrial faunal biogeography and diversity during 
the Oligocene epoch were likely influenced by geographic and climatic changes 
such as fluctuating Antarctic ice sheet formation, increased aridification and 
seasonality and a significant drop in global temperature and sea levels (Seiffert 
2007; Maravelis and Zelilidis 2012; Wade et al., 2012).  Additionally, the fall in 
 
sea levels opened routes between previously unconnected land masses and 
permitted migration (Kappelman et al., 2003; Figueirido et al., 2012; Maravelis  
and Zelilidis 2012) that may have, in turn, affected faunal extinctions during the 
late Eocene, and faunal diversity into the late Oligocene (Kappelman et al., 2003; 
Figueirido et al., 2012).   
 
Prior to the Eocene-Oligocene boundary, primates were widely distributed in 
Africa, the Arabian Peninsula, Asia and even the mid-latitudes of North America 
and Europe (Seiffert, 2007; Williams et al., 2010).  In the latter part of the 
Oligocene, primates in North America disappeared, as did many stem 
strepsirrhine and haplorrhine lineages in Africa and Afro-Arabia (Seiffert, 2007).  
Cool temperatures and habitat fragmentation in northern latitudes may have 
restricted primate latitudinal distribution, while equatorial Africa, despite 
experiencing decreased plant species diversity and cooler temperatures, retained 
widespread tropical forest habitats suitable for primates (Seiffert, 2007).  
Paleontological evidence shows stem anthropoids or catarrhines (i.e., the 
Oligopithecidae, Parapithecoidea, Propliopithecidae) at localities in Africa, Afro-
Arabia and Asia during the early Oligocene (Williams et al., 2010; Ducrocq et al., 
2011) although many of these lineages were extinct by the early Miocene (Seiffert 
2007).  Fossil remains of stem catarrhines such as Aegyptopithecus derive from as 
late as 29-30 Ma, but a scarce paleontological record from the mid-Oligocene 
makes discerning phylogenetic relationships or divergence dates between such 
 
stem taxa and crown catarrhines from the Oligocene-Miocene boundary very 
difficult (Seiffert, 2007; Zalmout et al., 2010).  Even the most informative  
sediments—such as those of the Fayum depression in Egypt—lack many primate 
remains (Steiper et al., 2004; Zalmout et al., 2010), resulting in a chronological 
gap in the primate paleontological record.   
 
The timing of the GGTA1 mutation can inform on the maximum bound for the 
phylogenetic split of catarrhines.  The mutation occurred in a basal catarrhine 
prior to the divergence of cercopithecoids and hominoids. Therefore, the 
phylogenetic split of these two groups must have occurred sometime after 28.1 
Ma.  It should be noted, however, that the timing does not indicate an exact 
divergence time for the catarrhine lineages or set a minimum bound for the split.  
The last common ancestor of OWMs and apes carrying the ΔGGTA1 gene may 
have survived for a long period of time after the mutation was introduced into the 
catarrhine lineage but prior to the divergence of cercopithecoids and hominoids. 
 
1.3 GGTA1 function in class Mammalia 
Loss of GT expression in catarrhines resulted in significant alteration to the 
surface carbohydrate biology of these primates, but neither the physiological 
function of αGal nor the metabolic consequences of inactivation of this locus in 
animals with a functional GT gene is currently known.  In non-catarrhine 
primates, the function of GGTA1 appears to be under strong physiological 
constraint, and the gene sequence has been highly conserved over evolutionary 
 
time (Koike et al., 2007).  Koike et al., (2007) suggest that inactivation of GGTA1 
gene may have been detrimental to individuals and that loss of GT gene function 
may have been possible only after its enzymatic role had been replaced, although 
they do not conjecture on what replaced the enzymatic function in catarrhines.  
The successful generation of experimental homozygous knockout (KO) pigs 
(Nottle et al., 2007) and KO mice (Thall et al., 1995) demonstrate that loss of 
GGTA1 activity is not lethal to an organism.  A few abnormal health conditions 
have been observed, including early-onset cataracts in some KO mice and 
breeding problems in certain KO pig lineages (Koike et al., 2007).  However, 
breeding of other KO pig lineages and KO mice (Tanemura et al., 2000) resulted 
in normal-sized litters that do not experience greater mortality or health defects 
than wild type counterparts.  This suggests that basal catarrhines could have 
experienced loss of GT function without an elevated risk of morbidity or 
mortality.  Alternately, the loss of αGal from tissue surfaces may have served a 
protective role during the evolution of catarrhines, and the benefits of losing gene 
function may have outweighed any negative effects. 
 
1.4 GGTA1 and infectious disease 
Infectious agents can be powerful drivers of evolutionary change.  Pathogens 
exert great selective pressures on susceptible populations and can even be the 
cause of extirpation or extinction (Pederson et al., 2007; Wyatt et al., 2008).  An 
example of the latter includes the species-level extinction of Rattus macleari after 
the introduction of a parasite, possibly Trypanosoma lewisi, to Christmas Island in 
 
the Indian Ocean (Wyatt et al., 2008).  The large rat population, which was 
immunologically naïve to the trypanosome parasite, was wiped out over a period 
of less than 20 years (Wyatt et al, 2008).  Infectious agents can also decimate 
populations of susceptible hosts and have devastating consequences for these 
populations.  Ebola virus, with up to 95% mortality rates, have reduced Gorilla 
and Pan populations in Africa over the past few decades (Leroy et al., 2004; 
Bermejo et al., 2006).  In regions of the Congo, outbreaks of Ebola have resulted 
in Pan troglodytes population declines of up to 83% (Bermejo et al., 2006).  This 
can lead to regional extirpation or bottlenecks in the population.  Occasionally 
individuals survive due to genetic resistance (previous mutations carried in their 
genome) or because new mutations have rendered them less susceptible than their 
counterparts.  This can be of adaptive significance to the entire species.   
 
One of the most studied examples of genetic resistance in the human population is 
the mutation CCR5- Δ32 on the leukocyte chemokine (C-C motif) receptor 5 
(CCR5).  The CCR5 gene locus was under selective pressure from pathogens 
encountered by the human population centuries ago, namely the bacterium 
Yersinia pestis and Variola virus (Hütter and Ganepola, 2011).   The Δ32 
mutation likely provided a level of resistance against these pathogens when they 
were scourges in the human population, and today, individuals who possess this 
mutation can also benefit due to their reduced risk of acquiring human 
immunodeficiency virus (HIV) (Hütter and Ganepola, 2011). 
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It has been hypothesized that the GGTA1 gene locus has also been under 
evolutionary selection due to pathogenic pressures (Galili et al., 1987; Galili et al., 
1988; Galili and Swanson, 1991; LaTemple and Galili, 1999).  Catarrhine 
primates that lack GT gene and αGal expression produce a natural antibody, anti-
Gal, which recognizes the αGal disaccharide with high affinity (Galili et al., 1987) 
and can induce phagocytic cell and complement activity (LaTemple and Galili, 
1999; Rother and Galili, 1999).  Production of natural antibodies that can 
recognize and effectively neutralize pathogens may be beneficial for animal hosts 
against a variety of parasites that express the αGal domain (Galili et al., 1984; 
Galili et al., 1988; Avila et al., 1989; Hamadeh et al., 1992; Ramasamy and 
Rajakaruna, 1997; Pingel et al., 1999).  Fresh sera with functional complement 
activity from different catarrhines can inactivate many different viruses that 
express αGal (Welsh et al., 1975; Welsh et al., 1976; Welsh, 1977; Rother et al., 
1995; Takeuchi et al., 1997; Welsh et al., 1998; Kim et al., 2007).  Sera from 
other mammals, including New World monkeys, rabbits, rats, mice and guinea 
pigs, do not lyse αGal-expressing viruses, as these species do not naturally make 
anti-Gal (Rother et al., 1995; Welsh et al., 1975; Welsh et al., 1976).  The ability 
of anti-Gal to neutralize pathogenic agents via the complement system has been 
heavily researched, and it is suggested that loss of αGT gene activity was favored 
during catarrhine evolution because it allowed immune recognition of pathogens 
expressing αGal (Galili et al., 1987; LaTemple and Galili, 1999; Rother and 
Galili, 1999).  As such, suppression of the GT gene would have been necessary to 
develop the ability to produce anti-Gal and not also stimulate an autoimmune 
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response (Galili et al., 1987).  Under this scenario, GT-deficient individuals 
would have been indirectly protected from αGal-expressing pathogens by the anti-
Gal activity. 
 
1.5 Selection for ΔGGTA1 gene during catarrhine evolution 
My alternative hypothesis is that positive selection for GT gene inactivation may 
have been favored because loss of αGal residues directly altered host 
susceptibility to infections.  The proteins on cell surfaces are involved in 
interactions with the surrounding environment, and the terminal carbohydrates 
that decorate these proteins are prime candidates for pathogens, including viruses, 
which can utilize carbohydrates as binding receptors or in other capacities 
(Olofsson and Bergström, 2005).  Historically, selective pressures from pathogens 
have led to major biochemical changes in carbohydrate biology of primates (Chou 
et al., 1998; Hayakawa et al., 2001; Gagneux et al., 2003; Varki and Varki, 2007).  
It is known that αGal can serve as a binding receptor for pathogens, as toxin A, 
produced by Clostridium difficile, binds to the αGal moiety on host cells and 
causes cytotoxic effects in these cells (Krivan et al., 1986; Clark et al., 1987; 
Teneberg et al., 1990; Phelps et al., 2003).   Hamsters are highly vulnerable to 
severe infections by C. difficile because they express high amounts of αGal on 
intestinal epithelial cells, and these sites are specifically targeted by the bacterial 
cytotoxin (Krivan et al., 1986).  Experimental infections of rabbit and rat brush 
border membranes and erythrocytes (Clark et al., 1987; Pothoulakis et al., 1991) 
have showed that αGal-capped membranes are the binding sites for C. difficile in 
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these species, and greater expression was associated with more targeting by the 
toxin (Krivan et al., 1986).  Krivan et al. (1986), also found that human red blood 
cells with the blood group B structure, Galα1,3Fucα1,2Galβ1,4GlcNac-R, would 
bind toxin A after treatment with a fucosidase. The enzymatic removal of fucose 
resulted in expression of Galα1,3Gal linkages on the cell membranes.  Humans 
can be infected with Clostridium spp. when intestinal or genital tract flora is 
disturbed (Agrawal and Garg et al., 2012), but the binding receptor in humans has 
not been determined.  It is suggested that because humans do not naturally express 
αGal, N-acetyllactosamine sites bearing molecular similarity to the Galα1,3Gal 
structure serve as binding sites (Krivan et al., 1986; Teneberg et al., 1990). 
As such, surface Gal residues are potential “hot spots” for selective evolution.    
 
For basal catarrhines living during the Oligocene, GT expression may have 
predisposed them to pathogenic agents able to exploit the GT pathway or its final 
glycosylation product, αGal.  Loss of GGTA1 activity and of surface αGal may 
have increased resistance to such pathogens by GT-deficient catarrhines relative 
to their GT-sufficient counterparts, resulting in selection for the ΔGGTA1 gene.  
The pathogenic agents at work during the Oligocene epoch are unknown, and 
therefore it is impossible to directly study the effects of such pathogens on 
α1,3GT positive or negative hosts.  However, we can conjecture about the role of 
host GT activity during viral infections in the past by studying the interactions of  
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GT-deficient and GT-sufficient hosts with modern day viruses.  Arguments can 
then be made regarding the potential for viral infectivity (or host resistance) in the 
presence or absence of GGTA1 gene activity.   
 
My current hypothesis does not contradict the theory that anti-Gal production was 
favored in the evolution of disease resistance for catarrhines.  Instead, it attempts 
to expand our understanding of the selection mechanism(s) that drove evolution 
of the GGTA1 gene.  In fact, the inactivation of the GGTA1 gene, coupled with 
the production of anti-Gal, point to strong selective pressure for reduced 
expression of the αGal epitope on the tissues of catarrhines.  It is possible that GT 
activity was lost due to neutral selection, through the accumulation of mutations 
on the gene locus that had no benefit or detrimental effect on the host.  This can 
be easily verified, as active host expression of GGTA1 or αGal would have no 
effect on the course of viral infections in that host.  It is also possible that certain 
viruses may preferentially infect hosts in the absence of GT expression.  This may 
not necessarily contradict my working hypothesis that GT activity facilitates the 
course of a viral infection.  Today, different viruses employ vastly different 
strategies to establish infections in hosts, and viruses that may have once 
specialized in exploiting the GT pathway may have modified their infection 
strategies since 28.1 Ma. 
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In order to demonstrate the possible adaptive significance of ΔGGTA1 for basal 
catarrhines, it is necessary to show that GT or αGal expression in hosts is 
required—or in the least—can enhance the capacity of infection for viruses 
relative to non-expressing hosts.  This will establish that GT or αGal expression 
may play a role in host susceptibility to viral infections.  Additionally, it is 
important to provide a possible mechanism by which viruses may utilize the GT 
pathway or sugar.  Viruses are known to utilize carbohydrate residues during 
entry into the cell (adsorption, penetration), or subsequently, during exit (release); 
as such, viruses may use surface αGal in this capacity.  Until now, glycan-based 
interactions of pathogens and αGal positive host-cells have received only limited 
investigation.  This aspect of the evolution of the α1,3GT gene – the 
differential ability of pathogens to infect host cells through utilization of the 
GT pathway or sites containing αGal – is the topic of this dissertation. 
 
1.6  Summary and Chapter goals 
The goal of this chapter was to provide an overview of the inactivation of the 
GGTA1 gene in basal catarrhines and of primate evolution during the Oligocene.  
Little is known about direct selective pressures underlying catarrhine evolution 
during this epoch; the period of catarrhine lineage evolution and the hominoid and 
cercopithecoid phylogenetic split.  Changes in global ecology such as colder 
temperatures and reduced habitats likely affected primate biogeography and 
diversity during the late Eocene and into the Oligocene.  We hypothesize that a 
pathogen, perhaps a virus, may have also played a role in shaping catarrhine 
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lineage divergence during this epoch.  Inactivation of the GGTA1 gene 
(molecularly clocked at the midpoint of the Oligocene epoch, ~28.1 Ma) resulted 
in a major change in carbohydrate biology for catarrhines, and possibly sites for 
pathogens to exploit.  The pressure from pathogens able to exploit the GT 
pathway may have been an impetus for selection of GGTA1 gene inactivation.  
Understanding the possible basis for selection of the mutated gene may inform us 
about some of the processes that helped shape primate lineage divergence during 
the Oligocene. 
 
1.6.1 Chapter goals 
Below is a brief description of the goals of each chapter of this dissertation. 
 
1.6.2 Chapter 2: Biology of GGTA1, anti-Gal and terminal carbohydrates 
In Chapter 2, I establish the evolutionary origins of GGTA1.  I review the role of 
anti-Gal as a protective factor in infectious diseases of primates.  I also discuss the 
importance of terminal carbohydrates in viral infections and provide several 
examples of pathogen-driven modifications of carbohydrate loci during primate 
evolution.  
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1.6.3 Chapter 3: Materials and methods 
In vitro and in vivo methods were utilized in order to understand the details of 
viral infections in GT positive and GT negative hosts.  Cell lines derived from 
mice were used for in vitro experiments and a mouse model was utilized for in 
vivo work.   
 
In Chapter 3, I describe the origins of the cell cultures and mouse lineages utilized 
in these experiments, as well as the significance of using a mouse model to study 
concepts in primate evolution.  I also describe the varied experimental methods 
utilized in this research. 
 
1.6.4 Chapter 4: Differential host susceptibility to viruses, in vitro results 
Various cell lines were used to establish differential susceptibility to viral 
infections in the presence or absence of GT activity in the host cell.  Preliminary 
results regarding the role of GT activity in viral infections were established in 
experiments using cultured cells lines because of the ease of manipulation.   
 
In Chapter 4, I describe the results from experiments with various cell lines.  I 
present evidence for GT-dependent differential susceptibility to viral infections, 
primarily with Sindbis viruses and herpes simplex viruses 1 and 2.  I show that 
differences in infections of GT-positive and GT-negative cell lines by the 
different viruses are based on the ability of the viruses to initiate infection in the  
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host.  Additionally, I show that αGal may play a role in the ability of viruses to 
establish infection.  I also discuss experiments that were not successful or resulted 
in ambiguous data. 
 
1.6.5 Chapter 5: Differential host susceptibility to viruses, in vivo results 
Differences in susceptibility to viruses can be tested in vivo using a mouse model 
to verify that in vitro findings can translate to the organismal level.  
In Chapter 5, I discuss the results of in vivo experiments.  I show that the same 
patterns of differential infection observed in the cell lines are observed in 
experimental mouse lines.  Clear and significant differences in susceptibility to 
infections are seen in GT deficient vs. GT sufficient mice with Sindbis virus 
infections of young mice and with herpes simplex 2 infections of adult mice.  I 
also show the results of experiments that generated inconsistent or ambiguous 
data.  
 
1.6.6 Chapter 6: Summary and Conclusions  
In Chapter 6, I examine the data and interpret findings from the previous chapters.  
Overall, infections of paired cell lines with differential expression of α1,3GT 
showed that certain viruses preferentially replicated in α1,3GT-positive cells, 
whereas others preferentially grew in cells lacking α1,3GT.  Viral growth and 
spread correlated with the ability of the different viruses to successfully initiate 
infection in the presence or absence of α1,3GT expression.  Additionally, 
differences in gross pathology, onset of disease symptoms and mortality are 
correlated with the presence or absence of α1,3GT host mice.  The current study 
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demonstrates that α1,3GT activity plays a role in the course of infections for 
certain viruses.  Furthermore, this study has implications for the evolution of 
resistance to viral infections in primates. 
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CHAPTER 2 
BACKGROUND ON GGTA1, ANTI-GAL, TERMINAL 
CARBOHYDRATES AND VIRUSES 
 
2.1 GGTA1 gene and αGal 
The genetic sequences that code for the ABO glycosyltransferases are found on 
the human homolog for the GGTA1 gene.  These glycosyltransferases likely form 
a family that arose as a result of gene duplications (Gastinel et al., 2001).  αGal is 
chemically similar to the ABO blood group antigens, and the transferases 
responsible for their biosynthesis share similarities in their catalytic domains 
(Gastinel et al., 2001).  The α-galactosyltransferase enzyme is a golgi 
transmembrane protein that catalyzes the transfer of a non-reducing galactose to 
an N-acetyllactosamine acceptor via the following reaction: UDP-Gal + 
Galβ1,3GlcNAc-RèGalα1,3Galβ1,4GlcNAc-R.  This results in Galα1,3Gal 
capped glycan chains.  In most mammals, including mice, rats, cows, rabbits, 
hamsters, pigs, dogs and non-catarrhine primates, αGal residues are found on the 
surface of nucleated cells and erythrocytes (Galili, 1993).  These residues cap the 
terminal ends of membrane-bound glycosphingolipids and glycoproteins (Galili et 
al, 1987) and in secreted N-glycosylated glycoproteins such as thyroglobulin, 
fibrinogen and IgG (Thall and Galili, 1990).  With the exception of sperm cells 
(Thall et al., 1995), the carbohydrate is abundantly expressed on the surface, up to 
106 molecules per cell (Galili, 1993).  Some tissue specificity in αGal expression 
does exist in certain mammals.  In rats, Griffonia simplicifolia B4 isolectin (BS 
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IB4), a molecule with high specificity for α-D-galactose groups, was found to bind 
to deeper layers in the epidermis and not at all in higher layers of the skin (Brabec 
et al., 1979).  The quantity of αGal residues expressed on tissue is also variable by 
host species and by the type of the glycoconjugate.  For example, bovine 
thyroglobulin has approximately 11 residues of αGal per molecule while Saimiri 
(squirrel monkey) expresses one residue per thyroglobulin molecule and mice 
express one αGal residue per every four thyroglobulin molecules (Thall and 
Galili, 1990).   
 
As expected, Macaca (macaque) and humans do not express a terminal galactose 
α(1,3) linked to a penultimate galactose (Gal-Gal linkage) on thyroglobulin, or to 
any other issue, because they have an inactive GGTA1 gene.  In humans, only 
three glycoconjugates found in red blood cells (RBCs) are known to express a 
terminally linked α-galactosyl: CTH, P1 and B antigen.  CTH and P1 have an 
α(1,4) linkage and B antigen has a fucose attached to the penultimate galactose 
(Galα1,3Fucα1,2).  BS Lectin can bind the terminal residue of the human blood 
B-antigen, but anti-gal binding—which is highly specific for the Gal-Gal 
linkage—is blocked due to the branched fucose (Galili et al., 1984).  Still, humans 
that express the B antigen (OB, BB or AB blood type) have reduced levels of IgG 
anti-Gal, possibly because there is some level of reaction between the antibody 
and the terminal galactose monosaccharide (McMorrow et al., 1997).   
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Of interest is the de novo-expression of αGal that has been observed on humans 
cells, including: senescent RBCs, pathologic RBCs such as those derived from 
thalassemic or sickle cell anemia-affected individuals (Galili et al., 1984) and 
cells from human mammary carcinomas (Castronovo et al., 1989).  Additionally, 
lung carcinoma cells will sometimes secrete β-interferon containing αGal 
carbohydrate chains (Kagawa et al., 1988).  In this way, αGal could play a role in 
autoimmune disease as human RBCs expressing αGal are targeted and lysed by 
anti-Gal mediated-complement lysis (Galili, 1993).  In humans, the GGTA1 gene 
is not transcribed, and although mice and pigs have alternative genes that can 
synthesize very small quantities of αGal epitopes (Milland et al., 2006), no other 
human gene has been discovered that can do this.  In the case of senescent RBCs 
expressing αGal, displaced GT-positive gut bacteria or their GTs can make their 
way into the circulatory system and become the source of αGal found on human 
RBCs (Hamadeh et al., 1996).  RBCs exposed to Klebsiella bacteria and their 
galactosyltransferases have been shown to incorporate bacterial αGal residues on 
their surfaces (Hamadeh et al., 1996).  Older RBCs compared to younger cells 
may be more likely to acquire αGal because their extended time in circulation 
exposes them to more lactosmaine acceptor molecules that can link αGal 
molecules (Hamadeh et al., 1996). Aberrant expression of αGal in other human 
tissues could indicate that within these tissues inactivation of GGTA1 may not be 
absolute, or a functional form of the polypeptide can be made under certain 
conditions (Galili et al., 1984).  
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Catarrhines without a functional GT gene still have homologous sequences to 
GGTA1.  Two GGTA1 homologs have been found in catarrhines by using probes 
from cDNA sequences derived from pigs, cattle and rodents (Jozaisse et al., 1991; 
Strahan et al., 1992; Koike et al., 2002).   The two loci evolved independently in 
the Haplorrhine (monkeys, apes and tarsier) lineage.  All haplorrhines have an 
orthologue of the gene, a processed pseudogene (PPG) that does not result in 
production of a functional protein (Larsen, et al., 1990; Jossaize et al., 1991; 
Koike et al., 2007).  The PPG appeared in the primate genome approximately 57.6 
Ma, after the Strepsirrhine/Haplorrhine split, but likely prior to tarsier divergence 
from the rest of the haplorrhines.  Putative grouping of the tarsier’s GT gene 
sequence places it with the PPG sequence (Koike et al, 2007).  Catarrhines still 
express the PPG and also an altered GGTA1 gene referred to as an unprocessed 
pseudogene (UPG) (Jozaisse et al, 1991; Koike et al., 2007).  The human 
homologues are found on chromosomes 12 (PPG) and 9 (UPG) (Jozaisse et al., 
1991).  
 
Comparisons of the human UPG with sequences from Macaca and mouse GT 
genes show little homology in various portions of the regulatory region (Koike et 
al., 2001; Koike et al., 2002).   The same is observed with comparisons of the 
regulatory regions (exons 1-3) of the more distantly related pig and mouse 
GGTA1 genes (Koike et al., 2001).  Although these differences affect gene 
regulation in pigs and mice, the enzymatic function is identical in both species 
(Koike et al., 2001), indicating that conservation in the regulatory region is not 
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essential for gene function.  In contrast, homologous genetic sequences in coding 
regions of the GT gene between primates, mice and bovine have been found 
(Larsen et al., 1990; Galili and Swanson; Jozaisse et al., 1991), indicating that the 
coding region is conserved.  In primates, including Homo, Pongo (orangutan), 
Macaca and Callithrix (marmoset), homology in the gene-coding regions (exons 
4-9) between apes and Callithrix was 94.7% and between Macaca and Callithrix 
was 92.4% (Koike et al., 2002).   
 
Several mutations in the coding regions of the Homo, Callithrix and Pongo genes 
(exons 7, 8 and 9) independently result in GT gene inactivation, but two 
mutations that independently yield a truncated gene product are shared by all 
three species: (1) a deletion on exon 7, and (2) a nucleotide substitution on exon 9 
(Koike et al., 2002).  Nucleotide alignment of genetic sequences that included 
strepsirrhines, platyrrhines, cercopithecoids, and hominoids indicate the point 
mutation on exon 7 in the catarrhine sequences, upstream of a region specifying 
an enzymatic catalytic domain, was likely responsible for GGTA1 inactivation 
(Koike, 2007).  The presence of the same mutation in cercopithecoids and 
hominoids, clocked at approximately 28.1 Ma, indicates that the gene was 
inactivated prior to an OWM-ape lineage divergence (Koike et al., 2007). 
 
It is of interest that KO pigs and KO mice still express relatively low quantities of 
αGal epitopes compared to their WT counterparts as a result of iGb3S 
glycosyltransferase activity (Milland et al., 2006).  Like α-galactosyltransferase, 
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this enzyme is part of the ABO-blood group family of glycosyltransferases and 
can catalyze the placement of a terminal Gal residue on glycoconjugates; 
however, in contrast to αGT enzyme activity, αGal capping via iGb3S is restricted 
to acceptors on iGb3 glycolipids (Milland et al., 2006).  This is of general interest 
because αGal is the major xenoantigen that induces hyperacute rejection in organ 
transplants to humans that come from pigs (Phelps et al., 2003). Therefore, organs 
from GT KO pigs may still be immunogenic.  This is of consequence to our 
current research because deciphering pathogen-host cell protein interactions may 
largely depend on absolute expression or non-expression of the protein of interest.  
Results must be interpreted in this context.  
 
2.2 Anti-Gal 
Catarrhines produce very high amounts of anti-gal antibodies that recognize the 
Galα1,3Galβ1,4GlcNAc-R epitope with high affinity (Galili et al., 1984; Galili et 
al., 1988).  In humans, anti-Gal is most commonly found as class IgG (IgG1, 
IgG2a, IgG2b, IgGc subclasses) comprising approximately 0.5-1.0% of total serum 
IgG (Galili et al., 1984), but it is also produced as classes IgM and IgA 
(LaTemple and Galili, 1998).  Humans produce other naturally occurring IgG 
molecules in blood, including anti-blood A and B and anti-T antibodies, that 
similar to anti-gal, display an anti-carbohydrate specificity (Galili et al., 1984).  
Production of natural antibodies is attributed to constant exposure to naturally 
occurring antigens over evolutionary time.  The constant exposure to 
gastrointestinal flora that expresses αGal on the cell wall, such as E. coli, 
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Salmonella and Shigella (Galili et al., 1988; Hamadeh et al., 1992), may stimulate 
the observed production of anti-Gal throughout the lifetime of humans as well 
(Galili et al., 1984).  
 
Besides commensal and pathogenic gut bacteria, a variety of other pathogens also 
express αGal residues, including protists (Ramasamy and Rajakaruna, 1997; 
Pingel et al., 1999).  Species of trypanosomatids (Leishmania sp. and 
Trypanosoma cruzi), the causative agents of leishmeniasis and Chagas disease, 
express lipids capped by galactosyl residues on the parasite’s surface during part 
of its life cycle, and infected hosts show significant increases in anti-Gal 
production compared to uninfected individuals (Avila et al., 1989).  Some 
individuals also develop a class of highly specific anti-Gal antibodies to the T. 
cruzi trypomastigote (the infective stage) that efficiently inhibits parasite growth 
through complement-mediated damage (Almeida et al., 1991).  The merozoites 
(infective stage) of Plasmodium falciparum, the most virulent malarial parasite of 
humans, also express αGal antigens and induce antibody-dependent complement-
mediated lysis (Ramasamy and Rajakaruna, 1997; Ramasamy et al., 1999).  
During egress from host cells, enveloped viruses often incorporate cellular 
membrane components into or onto the particle; and this includes galactosyl-
capped entities (Welsh, 1977; Welsh et al., 1998).  Viruses that express αGal then 
become antigenic to GT-negative species.  In this way, anti-Gal is speculated to 
restrict xenotransmission of viruses propagated in GT-positive species by  
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targeting them for complement-mediated inactivation (Welsh et al., 1975; Welsh 
et al., 1976; Welsh et al., 1978; Repik et al., 1994; Rother et al., 1995; Takeuchi et 
al., 1996; Kim et al., 2007).   
 
Mammalian species that naturally express GGTA1 accordingly do not make anti-
Gal, and are therefore tolerant to αGal-expressing viruses (Rother et al., 1995; 
Welsh et al., 1975; Welsh et al., 1976).  It is speculated that natural anti-Gal 
production was an adaptive response to pathogenic infection for catarrhine 
primates (Galili et al., 1987; LaTemple and Galili, 1999; Rother and Galili, 1999).  
However, for anti-Gal expression to be a driving force behind GT gene 
inactivation, anti-Gal production would have had to occur concurrently with the 
GGTA1 loss-of-function mutations.  Experimental mice that are double knockouts 
for the GGTA1 gene (Thall et al., 1995) do not naturally produce anti-Gal in sera 
and only produce low levels of IgG and IgM antibodies after initial exposure to 
antigenic epitopes (LaTemple and Galili, 1998).  A robust antibody response, 
comparable to titer levels found in humans, is only achieved by multiple 
immunizations (LaTemple and Galili, 1998).  This may indicate that upon 
historical loss of GT activity, anti-Gal-mediated protection was not immediate or 
wholly effective on primary exposures to αGal-expressing pathogens.  For a 
period of time, prior to the natural production of anti-Gal in the absence of 
external antigen stimulation, catarrhines still would have been highly susceptible 
to pathogens that expressed αGal epitopes.  As such, I suggest it is more plausible 
that production of natural anti-Gal occurred after inactivation of GGTA1.   
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I hypothesize that loss of GT gene expression may have been a response to 
pathogen-mediated selection on host genotype (GGTA1) or phenotype (αGal).  
Pathogens often utilize host cellular carbohydrates as binding receptors or in other 
capacities during the course of an infection.  The terminal carbohydrates that 
decorate cell surfaces function in various biological capacities for the host 
organism.  Due to their location at the outer edges of cells, carbohydrates are 
prime candidates for mediating interactions with other cells, other molecules, and 
with environmental agents.  As targets to foreign agents, surface sugars are 
expected to be under constant evolutionary pressures and are therefore key 
players in organismal health and disease. 
 
2.3 Terminal carbohydrates  
Many forms of life, including bacteria, plants and animals, express carbohydrate 
chains on the exterior surfaces of their cells.  The repertoire of glycans and the 
function they perform varies significantly depending on species and tissues, but 
the distribution of these structures in nature is indicative of their fundamental 
biological role.  Between 1-2% of animal genes are involved in glycan 
modification or synthesis (Bishop and Gagneux, 2007).  Relative to bacteria and 
plants, animals utilize a restricted set of carbohydrate units to create diverse and 
complex structures, generally arranged as four basic types of glycoconjates: N-
linked, O-linked, glycolipids and proteoglycans (Bishop and Gagneux, 2007).  
Patterns of glycan distribution can be limited to single species, be lineage-
specific, be similar across distantly related species or be widely conserved 
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(Bishop and Gagneux, 2007).  The different distribution patterns likely resulted 
from various processes such as the evolution of independent lineages following 
phylogenetic splits or from selection pressures imposed by pathogens (Bishop and 
Gagneux, 2007).   
 
2.4 Pathogen and host-cell glycan interactions 
During the course of infections, pathogens are involved in a variety of interactions 
with terminal carbohydrates on host cell surfaces and have evolved numerous 
strategies to exploit them.  Pathogens can also utilize glycosyltransferases to 
modify their own proteins, and this may result in increased virulence for that 
pathogen (Bishop and Gagneux, 2007).  Pathogens have also evolved ligands 
(lectins) that bind host carbohydrates, and they also produce molecules that mimic 
host glycans and can then bind to corresponding host ligands (Bishop and 
Gagneux, 2007).  Viruses, especially enveloped viruses, can also incorporate host 
cell carbohydrates or even proteins on their envelopes during egress.  This can aid 
to promote their infection cycles and also provide reduced immunogenicity in the 
host (Vigerust and Shepherd, 2007).  Host cell surface glycans are preferred 
binding sites for viruses to utilize as receptors (Olofsson and Bergström, 2005).  
Among these binding sites is heparan sulfate, a heavily glycosylated protein found 
on the surface of animal tissues.  Heparan sulfate often serves as initial binding 
sites for various mammalian viruses, including: Foot and mouth disease virus 
Type O (Jackson et al., 1996), Dengue virus and yellow fever virus (Germi et al., 
2002), herpes viruses (WuDunn and Spear, 1989), and Sindbis viruses (Byrnes 
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and Griffin, 1998).  Other commonly exploited epitopes are sialic acid 
monosaccharides.  The carbohydrate chains of sialic acids are structurally very 
similar to αGal glycans (Fig. 2).  It is possible that αGal molecules play a role 
analogous to sialic acid during pathogen infection.   
 
Sialic acids are the most commonly expressed terminal carbohydrates on cells of 
vertebrates (and other animal phyla) and are essential for embryonic development 
(Varki, 2010).  Sialic acid residues are transferred to glycoconjugates by 
sialyltransferases.  Both sialyltransferases and α-galactolystransferases function 
within the trans-golgi network and link terminal residues to N-acetyllactosaminyl 
Galβ1,4GlcNac-R carbohydrate chains (Joziasse et al., 1991; Thall and Galili, 
1990).  This results in competition for linkage of the terminal unit (either sialic 
acid or αGal) to the common acceptor (Gorelik et al., 1995).  It is of interest to 
consider that because α-galactosyl residues can utilize the same position on 
glycoconjugates as sialic acid, they may perform corresponding functions during 
pathogen infections, and may also be subjected to similar evolutionary pressures.  
During evolution, certain linkage expression patterns of sialic acid in specific 
vertebrate taxa underwent major genetic changes, but the same domains remained 
conserved for millions of years in the majority of vertebrate taxa, including 
closely related species (Gagneux et al., 2003).  This indicates that selective 
pressures on these domains may be species or lineage-specific.  The primate 
evolutionary record yields good evidence of alterations of sialic acid loci under  
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selection in response to pressures exerted from pathogens, notably the ST6 beta-
galactosamide alpha 2,6-sialiyltranferase 1 (ST6GAL1) gene and cytidine 
monophosphate-N-acetylneuraminic acid hydroxylase (CMAH) gene. 
Figure 2: αGal residues on a carbohydrate chain (top) and sialic acid-capped 
carbohydrate chain (bottom), as part of glycoproteins or glycolipids on the surface 
of mammalian cells.      
2.4.1 Alpha 2,6 linked sialic acid and influenza A 
Influenza A and B viruses are among several viruses that can use sialic acid as an 
attachment receptor to gain entry into host cells (Varki and Varki, 2007), and they 
also encode their own sialidases (sometimes called neuraminidases) to facilitate 
their release from these cells (Weis et al., 1988; Susuzki et al., 2000).  Influenza A 
viruses attach to host cell terminal sialic acid residues via the haemagglutin (HA) 
glycoprotein on their surfaces; therefore, virus host range is defined by the 
receptor binding site of the HA they express (Vines et al., 1998; Angata and 
Varki, 2002).  HA of avian influenza A viruses generally recognize different 
carbohydrate linkages (SAα2,3Gal) than human influenzas (SAα2,6Gal) do, 
possibly because the linkages orient the terminal carbohydrate in an energetically 
favorable position (Vines et al., 1998).  Among primate taxa, certain influenza 
 
viruses cause disease in humans but not in other great apes, and vice versa 
(Gagneux et al., 2003).  This is because influenza viruses infecting the other great 
apes use SAα2,3Gal linkage specificity (Gagneux et al., 2003; Varki and Varki, 
2007).  Humans express SAα2,3Gal linkages but these sites are found lower in the 
airways relative to SAα2,6Gal sites, and virus may not travel that far down during 
host exposure (Varki and Varki, 2007).  It is hypothesized that the ST6GAL1 
gene, the gene responsible for the enzyme that biosynthesizes the placement of 
the terminal sialic acid to α2,6Gal, has undergone altered regulation in the 
hominin lineage (Gagneux et al., 2003), to become the predominantly expressed 
sialic acid linkage in the upper airways.  Avian influenzas can sometimes cross 
the species barrier via an intermediate host—pigs—which express both 
SAα2,3Gal and SAα2,6Gal domains on the upper respiratory airways (Varki and 
Varki, 2007).  The lack of SAα2,3Gal expression in human upper airways is fairly 
protective against direct transmission; the 1918 influenza pandemic is an example 
of a successful transmission event of a bird virus to the human population that 
could utilize both α2,3Gal and α2,6Gal linkages (Varki and Varki, 2007). 
 
2.4.2 NeuAGc and Malaria 
The vector-borne apicomplexan, Plasmodium falciparum, is the causative agent 
of the most virulent form of malaria in humans.  P. falciparum evolved from P. 
reichenowi, the malarial parasite species that infects our closest living relatives, 
chimpanzees (Pan troglodytes and P. paniscus) (Rich et al., 2009).  Pan, like 
other apes and most other mammals (except humans), express the terminal sialic 
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acid Neu5Gc, and in smaller quantities also its metabolic precursor Neu5Ac, on 
erythrocytes (Chou et al., 1998; Hayakawa et al., 2001).  The infective stage of 
Plasmodium, the merozoite, invades host erythrocytes primarily via binding the 
host glycoprotein A (GYPA) receptor that is capped by sialic acid (Martin et al., 
2005).  P. reichenowi preferentially utilize the sialic acid, Neu5Gc, to cause 
infection in chimps, but P. falciparum binds Neu5Ac in humans (Orlandi et al., 
1992).  This is because between 2.8 and 3.2 Ma, prior to the appearance of Homo, 
an exon deletion in the cytidine monophosphate (CMP) N-acetylneuraminic acid 
hydroxylase (CMAH) gene responsible for conversion of Neu5Ac to Neu5Gc, 
rendered our ancestors unable to produce the Neu5Gc terminal domain (Chou et 
al., 1998; Hayakawa et al., 2001: Hayakawa et al., 2006).  Only Neu5Ac, the most 
common sialic acid found in modern day humans, accumulates on RBCs 
(Hayakawa et al., 2001; Rich et al., 2009), while the Neu5Gc residue is now 
antigenic (Brinkman-Van der Linden et al., 2000).  It is hypothesized that 
pressure from the ancestral P. reichenowi parasite may have driven selection for 
the mutated gene during hominin evolution that then provided natural resistance 
to infection (Rich et al., 2009).  For some time, our ancestors would have enjoyed 
reduced susceptibility to malaria, but subsequently, prior to ~10,000 years ago, a 
population of P. falciprum had evolved binding specificity for Neu5Ac, and 
malaria, abetted by agriculture, once again became a major human pathogen 
(Hayakawa et al., 2001; Rich et al., 2009).  In modern human populations, the 
sialylated GYPA domain is highly polymorphic.  This suggests that even today, 
this site is under high selection, presumably due to continued pressure exerted 
 
from Plasmodium (Martin et al., 2005) or numerous other pathogens that can 
exploit this moiety.  These include various viruses such as Newcastle disease 
virus, Sendai virus and human parainfluenza viruses (Angata and Varki, 2002).  
Although the sialyltransferase responsible for addition of Neu5Ac to glycan 
chains is under evolutionary constraint, modification of the GYPA protein 
scaffolding has been an effective host strategy for pathogen evasion (Martin et al., 
2005).   
 
It is of special interest, and is perhaps not unexpected, that changes in 
glycosylation may exert wide-ranging effects on the organism and these effects 
may themselves be of evolutionary significance.  Siglec-1 (sialic acid binding 
immunoglobulin superfamily lectin) is found in all mammals and has strong 
binding affinity for Neu5Ac (Brinkman-Van der Linden et al., 2000). Since the 
inactivation of the CMAH gene, human tissue provides abundant ligands for this 
lectin, and its expression is especially notable on macrophages in splenic tissue.  
The localization and expression of siglec-1 may provide humans an advantage 
against sialic acid-expressing pathogens, increasing their recognition by 
phagocytic cells (Brinkman-Van der Linden et al., 2000).  Other studies with 
knockout mice for the CMAH gene show that loss of Neu5Gc expression in mice 
yields phenotypes that appear, to some degree, to have analogues in humans.  
Compared to control mice, Neu5Gc-deficient mice have age-related hearing loss 
and slow wound healing; these are derived traits also associated with humans after 
divergence from our common (CMAH gene-expressing) ancestors with 
 
chimpanzees (Hedlund et al., 2007).    Perhaps of more significance is the 
possibility that Neu5Gc, which is expressed in low quantities in the brain of apes 
and other mammals, may have restricted brain expansion in ancestral primates 
(Varki, 2001; Chou et al., 1998; Chou et al., 2002).  The fixation of the gene, 
sometime by 2 Ma, coincides with a significant increase in hominin cranial 
capacity as evidenced by the fossil record (Chou et al., 2002).  Lastly, molecular 
analyses of CMAH gene sequences between different human ethnic groups, Pan 
and Gorilla, have even been employed in assessing hominin dispersal out of 
Africa and in reconstructing modern human origins (Hayakawa et al., 2006). 
 
2.5 Experimental mouse models 
Cellular functions, as studied in vitro, may not always translate accurately to 
functional studies in a complex system.  Cell lines can be very useful for testing 
questions about phenomena at the cellular or molecular level, but for questions 
that concern evolution, it is essential that in vitro findings be verified at the 
organismal level.  Ideally, research based on a species of interest would also be 
tested on that animal species, as they are the test subjects.  However, several small 
mammal species are used as models in biological research in lieu of the species of 
interest, which is often humans.  It is neither ethical nor always feasible to 
experiment directly on humans.  Codes of ethics in research also extend to our 
closest relatives, nonhuman primates, because, among other concerns such as cost 
and availability, many primate species are endangered. 
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Mice are among the most commonly used animal models in experimental research 
because they are less expensive, are easier to genetically manipulate and have 
faster reproduction times with more numerous litters compared to larger 
laboratory mammals (Messaoudi et al., 2011; Bähr and Wolf, 2012).  These traits 
are especially beneficial when a great number of experiments must be completed.  
However, a major criticism of utilizing mice is that they are not suitable 
substitutes for studying the biology of other organisms (most notably humans) 
due to their genetic distance from humans.  Additionally, inbred laboratory mice 
do not generally harbor the same species of pathogens as humans, and for disease 
research this limits the diversity of pathogens and variability in responses from 
host mice that can be examined (Messaoudi et al., 2011).  Despite these 
limitations, a remarkable amount of information about fundamental cellular and 
molecular functions is known from using mouse models (Messaoudi et al., 2011).  
Because of the relative ease of genetic manipulation, mice with desired mutations 
often can be generated for studies of human issues (Crawley, 1999), and the 
mutated homologous loci result in genetic and phenotypic similarities in mice and 
humans (Bedell et al., 1997).  Laboratory mice are even useful for studies of 
nonhuman primates, and serve as models for one of the most severe pathogens 
affecting nonhuman primates, Ebola virus (Bray et al., 1998; Bradfute et al., 
2012).  For my dissertation research, working with a nonhuman primate model 
was not possible due to cost and laboratory capabilities.  Fortunately, genetically-
altered mice were readily available for testing the proposed hypotheses. 
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2.6 Viruses 
Two groups of viruses were predominantly used in this study to understand the 
role of GGTA1 activity and the terminal carbohydrate, αGal, in the course of viral 
infections: 1) Sindbis (SINV) group of viruses and 2) herpes viruses.  Clearly, the 
viruses examined in this study would not have been the putative selection agents 
of 28 million years ago.  As with any study focused on reconstructing the 
evolutionary past, it is not possible to directly evaluate the selection agents or the 
effect these agents may have had on primates millions of years ago, but we can 
make inferences based on strongly supported data.  Therefore, this study should 
be taken as a proof of principle of what could have happened, rather than a factual 
account of what did occur. 
 
2.6.1 Sindbis virus (SINV) and SINV-related viruses 
The arthropod-borne alphaviruses are distributed worldwide: Old World 
alphaviruses include Sindbis (SINV), West Nile (WNV), Semliki forest (SFV) 
and Chikungunya (CHIK) viruses, and New World alphaviruses include Eastern 
equine encephalitis (EEE) and Western equine encephalitis (WEE) viruses 
(Strauss et al., 1994).  The prototype alphavirus, Sindbis virus, is an enveloped, 
positive-sense RNA virus with a genome of 11,703 nucleotides (Strauss et al., 
1994).  SINV (strain AR339) was originally isolated from the Culex mosquitos in 
Sindbis, Egypt in 1952 (Taylor et al., 1955), but it is geographically widespread, 
and has been collected from infected mosquitos in Europe, Africa, Asia and 
Australia (Johnson, 1965; Kurkela et al., 2008).  Culex and Culiseta mosquitos are 
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primary vectors of SINV (Taylor et al., 1955; Johnson, 1965; Kurkela et al., 
2008), although ixodid (hard) tick transmission has been documented (Taylor et 
al., 1955; Gresikova et al., 1978).  Various avian species, including game and 
passerine birds, serve as reservoirs for the virus (Taylor et al., 1955; Sammels et 
al., 1999; Kurkela et al., 2008), and it is possible that the geographical 
dissemination of the virus is due to the migrations of viremic birds (Sammels et 
al., 1999; Kurkela et al., 2008).  A broad range of animal hosts, such as 
amphibians and mammals (including humans), are susceptible to SINV (Johnson, 
1965).  In humans, disease from SINV infections can range from asymptomatic to 
chronic, and although generally not a health threat, epidemics have occurred in 
Europe and Africa (Sammels et al., 1996; Kurkela et al., 2008).  
 
In mice, SINV is neurovirulent and is generally fatal if the virus reaches the 
central nervous system (CNS), but infection is restricted if only extraneural tissue 
is involved (Johnson, 1965).  The virus replicates in skin, skeletal muscle and 
fibroblast tissue, and then disseminates to the CNS via a viremia (Klimstra et al., 
1998; Ryman et al., 2000).  Lesions occur in both skeletal muscle and in the CNS, 
but there is no significant pathology in infected liver or abdominal organs (Taylor 
et al., 1955).  In the brain, SINV induces apoptosis in spinal cord and brain cells 
(which do not regenerate), and the loss of this tissue correlates with death in mice 
(Lewis et al., 1996).  Most strains of SINV are lethal to neonatal mice, replicating 
to very high levels and causing ataxia and death by five days post infection 
(Taylor et al., 1955; Klimstra et al., 1998).  In weanling mice, the virus has a 
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prolonged incubation period that results in delayed onset of symptoms (Taylor et 
al., 1955); by approximately two weeks of age, mice have reduced viral load and  
no longer succumb to infection (Taylor et al., 1955; Reinarz et al., 1971; Lewis et 
al., 1996).  In these mice, virus replication and viremia are limited primarily by a 
robust IFN-α/β response, which increases with age (Ryman et al., 2000). 
 
SINV are easily adaptable to a variety of cells in vitro, and strains used in 
laboratory settings can be modified by their cell culture passage history 
(McKnight et al., 1996).  For example, the virus can acquire the ability to utilize 
heparan sulfate as an attachment receptor when grown in BHK cells, even after 
one passage (Klimstra et al., 1998).   SINV viruses may also become attenuated 
after serial passage (McKnight et al., 1996).  Additionally, SINV isolates, mutants 
or laboratory strains may differ in their level of virulence in young and adult mice 
(McKnight et al., 1996).  S.A.A.R86 (South African arbovirus no. 86) is a natural 
virus isolate of the SINV group of alphaviruses and is genetically distinct from 
the wild-type (WT) AR339 strain (Heise et al., 2000; Ryman et. al, 2000).  This 
isolate is neurovirulent and lethal to adult mice when inoculated intracranially 
(i.c.) (Russell et al., 1989; Ryman et al., 2000); this is due to a mutation in its 
nonstructural protein 1 (Heise et al., 2000).  The TR339 strain is a laboratory-
generated clone that is similar to AR339, but expresses cell-culture adaptive 
mutations such as heparan sulfate binding, and is more virulent to neonatal mice 
compared to culture-adapted strains (McKnight et al., 1996).  The TE12-GFP 
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mutant is a recombinant virus encoding a green fluorescent protein (GFP) gene 
under control of a subgenomic promoter (Wang, 2008).  The GFP mutant  
replicates to similar titers as the parental TE12 mutant (Wang, 2008).  TE12-GFP 
was constructed from the (avirulent) Toto1101 and (virulent) NSV strains and is 
highly lethal to suckling mice, but not adult mice (Lustig et al., 1988).   
 
2.6.2 Herpes viruses 
The alphaherpesviruses, herpes simplex virus type 1 (HSV-1) and type 2 (HSV-
2), are large, double stranded DNA viruses that are ubiquitous human pathogens.  
These viruses cause primary (lytic) infections in skin and mucosal epithelia and 
then travel to the peripheral and central nervous system where the viruses 
establish latent infections in ganglia (Sodeik, 2007).  Lytic infections can recur 
when the virus reactivates and travels back to the peripheral sites of infection 
(Sodeik, 2007).  
 
Mice serve as models for infections of these human pathogens (Baker and Plotkin 
et al., 1978; Manickan and Rouse, 1995).  The pathogenesis and neuroviruluence 
of HSV-1 and 2 can differ, as shown in experimental mice.  This is often a 
consequence of the route of infection.  By intravaginal infections, both virus 
strains produce infections in the vulva and vagina, without much involvement of 
peripheral organs.  The virus then disseminates to the CNS where infection can 
lead to fatal encephalitis (Renis et al., 1976).  Almost any route of inoculation 
with HSV-2 results in apparent hepatic necrosis, but similar infections with HSV-
1 seldom result in liver involvement or damage (Mogensen et al., 1974; Renis et  
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al., 1976).  Severe infections with herpesviruses in humans (e.g., HSV-2, VZV, 
EBV) often involve dissemination to various organs and exhibit liver pathology 
(Renis et al., 1976). 
 
The HSV-1 GFP (KOS 1.1) strain is a mutant that expresses a GFP-ICP8 fusion 
protein.  The ICP8 protein, an early DNA-binding protein that functions in viral 
nucleic acid and protein localization to replication compartments, as well as 
regulation of late gene expression in host cells, is mutated in this recombinant 
virus (McNamee et al., 2000).  The virus is able to effectively initiate infection, 
but DNA replication and late gene expression in host cells are affected, and 
subsequent virus production is significantly reduced compared to that of wild type 
HSV-1 (Gao and Knipe, 1991; McNamee et al., 2000; Taylor et al., 2003). 
 
The murine gammaherpes virus 68 (γMHV-68) is a member of the 
gammaherpesviruses.  The virus is closely related to the human Epstein-Barr virus 
(EBV; the most common agent of mononucleosis) and Kaposi’s sarcoma-
associated herpesvirus.  In mice, infections with γMHV-68 most commonly occur 
through the nasopharyngeal tissue, and the virus replicates in the lung epithelial 
cells (Michaud et al., 2010) where it can cause lymphoproliferative disease 
(Sunil-Chandra et al., 1992).  During primary infection, the virus can be recovered 
from the lung and various peripheral tissues such as kidneys and spleen (Sunil-
Chandra et al., 1992).  In the spleen, the primary organ where virus persists, 
infection leads to enlargement of the organ (splenomegaly) (Sunil-Chandra et al., 
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1992).  Latent infection occurs when the virus migrates from lung and other 
tissues to B lymphocytes (as seen with EBV infections in humans) and 
macrophages (Sunil-Chandra et al., 1992; Michaud et al., 2010).  Several months 
to a year after infection, mice can develop lymphomas or lymphoproliferative 
disease (Sunil-Chandra et al., 1992). 
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CHAPTER 3 
 METHODS AND MATERIALS 
 
3.1 Cell lines 
For in vitro studies, three pairs of cell lines (two mouse lines and one human line) 
were used to verify that findings were not unique to a single type of cell line or 
organism from which the cell line derived.  The GT KO mouse embryonic 
fibroblast (MEF) cell line is derived from GT-deficient transgenic mice and 
therefore lacks expression of αGal.  MEFs from 129 WT mice (GT-sufficient) 
(Jones et. al., 1996) were acquired from Dr. Stephen Jones at UMMS, as controls.  
Both cell lines were cultured as monolayers in 10cm petri plates because 129 WT 
MEFs appear to grown better in dishes than in flasks.  Cultured cells were fed 
with GIBCO Dulbecco modified Eagle’s medium (EMEM) and supplemented 
with 10% fetal bovine serum (FBS) and 2.5% penicillin and streptomycin and 
2.5% L-glutamine.  WT 129 cells produce debris after initial passages, so they 
were used after third passage for experiments, but after 4-5 passages, cells were 
no longer viable for experimentation. 
 
A pair of modified human melanoma cell lines, the SK-N-MC cells (Biedler et al., 
1973), were transduced with a retroviral vector containing a full-length porcine 
GT cDNA (pLGTSN) or a retroviral vector without insert (pLXSN) (Welsh, 
1998). The GT-modified human cell lines were designated as SK-N-MC pLXN 
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(SK) (inactive GT gene) and SK-N-MC pLGTSN clone 10 (SK-GT) (active GT 
gene).  These cell lines were grown in GIBCO Roswell Park Memorial Institute  
(RPMI) medium 1640 and supplemented with 10% fetal calf serum (FCS) and 
2.5% penicillin and streptomycin, 2.5% L-glutamine and the selective antibiotic 
for the Neomycin resistance gene, G418 (500μm/mL). 
 
The BL6 (bladder 6) cell line, a subclone of the highly invasive B16 melanoma 
cell line, was isolated from the bladder wall of C57BL/6J mice (Hart, 1979; Poste 
et al., 1980).  Continuous selection for metastatic capabilities resulted in BL6 
cells that spontaneously lost biosynthetic αGT activity (Gorelik et al., 1995).  
These melanoma cells were later transfected with the murine α1,3GT gene cDNA 
to create a cell line, designated BL6αGT, with similar characteristics to the 
parental cell line except for αGal expression on the cell surface (Gorelik et al., 
1995).  We used the BL6αGT (GT+) cell line as controls for BL6 (GT-) cells.  
Both cell lines were cultivated as monolayers in GIBCO minimum essential 
medium (MEM) and supplemented with 10% fetal calf serum (FCS) and 2.5% 
penicillin and streptomycin and 2.5% L-glutamine.  The stable transfectant 
BL6αGT line seems to maintain the inserted gene without selection media, but the 
antibiotic G418 can be utilized to reduce the possibility it will lose the gene (U. 
Galili, pers. comm.).  Cells were maintained by freezing at -80° in aliquots of 
approximately 1x106 cells/vial, in 90% fetal calf serum and 10% DMSO.   Two 
different clones of the BL6 and BL6αGT cell lines were used throughout the 
course of the study, because the initial set of cells acquired began exhibiting 
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differences in morphology and growth rates, and BL6αGT displayed variable 
expression of αGal on its’ surface.  The second set of cells appeared more stable.  
Several experiments initially completed on the first set of cells, such as time 
courses and adsorption assays, were repeated on the second set.  Results were 
consistent in both sets of cell lines.   
 
SK and SK-GT cell lines were tested for surface expression of αGal by staining 
with monoclonal anti-gal antibody, M86 (Enzo Life Sciences), and secondary 
allophycocyanin (APC)- or R-phycoerythrin (R-PE)- conjugated goat anti-mouse 
IgM (Invitrogen).  BL6 and BL6αGT were regularly monitored for αGal 
expression during the course of the study with M86 and secondary APC or R-PE, 
or alternatively, with fluorescein isothiocyanate (FITC)-conjugated BS lectin 
(BSl-B4) from Bandeiraea simplicifolia was used as an αGal binding lectin 
(Sigma-Aldrich).  BSl has broader specificity than anti-gal, as it has binding 
capacity to the GalNAc and Galα1,4Gal carbohydrates, but anti-Gal is specific 
only to a galactose in an α(1,3) linkage to a penultimate galactose (Galili et. al, 
1984).  BSl can also bind to Galα1,3Fucα1,2Gal, as demonstrated by 
hemagglutination of erythrocytes derived from Hylobates and Pongo (Galili et al., 
1987).  Fluorescence was measured using a BD Biosciences LSR II flow 
cytometer with FACS Diva software and analyzed using FlowJo software 
(TreeStar Inc., Ashland, OR).  
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3.2 Knockout mice 
GT KO mice [C57BL/6J x DBA/2J x 129sv] were generated by disruption of the 
α1,3GT gene by homologous recombination (Thall et al., 1995).  GT KO mice 
were backcrossed onto the C57BL/6J background for well over ten generations in 
the laboratory of Dr. Uri Galili in the Department of Medicine at UMMS.  
Breeding pairs were kindly donated to our laboratory, and mice were bred at the 
UMMS animal facilities.  Adult C57BL/6J mice, acquired from Jackson 
Laboratories, were used as control mice.  C57BL/6J (B6) suckling mice were bred 
at the UMMS animal facilities.  During the course of this study the GT KO mice 
generally bred well, with litter sizes that ranged between 2-10 pups, and mice 
only displayed occasional periods of reduced reproductive output.  The mice 
showed no outward signs of abnormal health conditions, except a few incidents of 
dental malocclusion and rare cases of hydrocephaly or rectal prolapse.  
 
3.3 Mouse crosses 
Different mouse strains have variable resistance to HSV infections (Kastrukoff et 
al., 1985).  Both 129 and DBA/2 mice are genetically more susceptible to HSV 
infections than B6 mice.  Because B6 mice are utilized as controls to KO mice in 
in vivo experiments, any underlying susceptibility that is a result of the KO 
genetic background would skew results.  The backcrossing history of KO mice 
into the B6 line suggests that the disrupted GGTA1 locus should be well 
recombined into the B6 genotype.  However, further outcrossing and backcrossing 
mice will provide some assurance that our loci of interest will further recombine 
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into the B6 background and that possible genetic linkages from the DBA/2 and 
129 backgrounds will be disassociated.  Male C57BL/6J mice were mated with 
female GT KO to produce an F1 heterozygous generation.  The heterozygotes 
maintain active GT expression.  Backcrosses (F1xWT and F1xKO) were then 
created by mating the F1 generation with individuals of the parental strains.  All 
F1xWT crosses had functional GT expression while F1xKO crosses had a 50% 
probability of being homozygous for the KO gene.  It would be expected that the 
susceptibility of an F1xKO mouse that inherited two alleles of the inactive α1,3GT 
locus would respond in the same way as a GT KO animal, to herpesvirus 
infection.  F1xF1 intercrossed mice were also created, but were utilized in few 
experiments.  All mice were analyzed for GT activity by  
testing for surface expression of αGal.  Anti-Gal or BS lectin binding of 
peripheral or cardiac blood cells was performed; BS lectin was more adequate for 
testing αGal expression in blood. 
 
3.4 Enveloped viruses 
The following enveloped viruses were predominantly used in these studies: 
Sindbis virus (SINV) HR strain (Burge and Pfefferkorn, 1966); S.A.A.R86, 
TR339 and TE12-GFP strains obtained from Dr. Dennis T. Brown at North 
Carolina State University; herpes simplex type 2 (HSV-2) strain MS (Rosenberg 
et al., 1972); herpes simplex type 1 (HSV-1) KOS1.1 strain (Babu et al., 1996)  
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obtained from Dr. David Knipe, Harvard; HSV-1 KOS 1.1 GFP (green 
fluorescent protein) ICP8 mutant (McNamee et al., 2000) obtained from David 
Knipe; mouse γ-herpes virus-68 (γMHV-68) obtained from Dr. Blake Tomkinson.   
 
Table 1 shows additional viruses that were screened during the study. These 
viruses were readily available for use in the laboratory of Dr. Raymond Welsh at 
the UMMS.  Viruses were grown in Vero cells, which do not express αGal; 
therefore the carbohydrate was not expressed on the viral envelope.  Several 
SINV and herpes viruses were also grown in L929 cells for experiments where 
αGal expression on the viral envelope was needed. Additionally, murine 
cytomegalo virus (MCMV), strain Smith, was grown in GTKO cells that do not 
express αGal and had an initial stock titer of 3.5x107. 
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TABLE 1: Viruses screened during this study 
aViral stocks were grown in either αGal-negative Vero cells or αGal-positive L929 
cells and were then titrated on Vero cell monolayers. 
b Titers shown are mean viral titers from duplicate tests. 
c – denotes that virus was not grown in that cell type. 
Viruses were propagated in Vero cells (Chlorocebus sp. kidney cell line) or L929 
cells (C3H mouse fibroblast cell line) and harvested at the peak of infection.  Cell 
debris was removed from culture fluid by centrifugation.  Culture fluid from 
virus-infected cells was titrated by plaque assay on Vero cell monolayers.  The 
concentration of virus (multiplicity of infection or MOI) used for infections in our 
assays was based on titrations in Vero cells.  Vero cells do not express αGal on 
their surfaces, and viruses propagated in Vero cells do not carry αGal 
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carbohydrates on their envelopes.  L929 cells express αGal on their surfaces, and 
viruses grown in L929 cells have αGal incorporated into their envelopes (Welsh 
et al, 1998).  Vero and L929 cells were maintained as monolayers in MEM 
supplemented with 10% FCS and 2.5% penicillin and streptomycin and 2.5% L-
glutamine.   
 
3.5 Time courses  
For time courses of viral infections, GT-positive and GT-negative cells were 
seeded in 6-well plastic plates and left to adhere anywhere from 4 and 24 h prior 
to infection.  The period of time cells were left to adhere to plates did not affect 
the results of the time course infections.  Before adding virus, media were 
removed and replaced with 1mL of complete MEM.  Virus was diluted to an MOI 
from .01 to 1.0 in MEM, added to the cell monolayers, and left for adsorption 
periods of 60 minutes for time courses.  Culture fluid with unabsorbed virus was 
removed, and the cells were washed twice and re-fed with 2mL MEM.  Culture 
fluid from infected cells was collected up to 72 hours post infection (h pi) and 
titrated by plaque assay on Vero cell monolayers.  Monolayers infected with GFP 
viruses were observed using a Nikon Eclipse fluorescence microscope, and the 
images were analyzed with NIS-Elements Advanced Research imaging software; 
alternatively, cells were harvested by dispersion with trypsin and analyzed by 
FACs analysis at each time point. 
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3.6 γMHV-68 time course and PCR analysis 
Infections with γMHV-68 were completed on BL6 and BL6αGal cells, and virus 
was quantified by PCR.  Cells were seeded in 6-well plastic plates and left to 
adhere for 24 h prior to infection.  Before adding virus, media was removed and 
replaced with 1mL of complete MEM.  Virus was diluted to an MOI of 1.0 in 
media, added to the cell monolayers, and left for adsorption periods of 60 
minutes.  Culture fluid with unabsorbed virus was removed, and cells were 
washed twice and re-fed with 2mL MEM.  Cells were harvested at 24, 48 or 62 h 
pi, counted, and then prepped for PCR analysis using the CFX detection system 
(BioRad Laboratories, Hercules, CA).  The two amplification primers for the viral 
ORF49 were as follows: forward primer, 5'-CCTGGCCATGGTTACATACTC-3; 
reverse primer, 5'-GGAACATAATCCATAAGCAGGGT-3' (Lee et al., 2007).  
No calibration standard was readily available for use, so quantification of viral 
copy number (absolute quantification) was not possible.  Instead, samples were 
normalized using a reference gene, the housekeeping gene β-actin, found in host 
cells, to control for relative differences in spleen size.  DNA synthesis was 
monitored using the nucleic acid stain SYBR Green I.  Samples of γMHV-68 
from culture fluid and water were used as positive and negative controls, 
respectively.  PCR conditions were as follows: 95°C for 10 mins denaturation, 
and 95°C for 30 s, 62°C for 30 s and 72°C for 30 s, for 37 cycles.  Samples were 
tested in duplicate.  The quantification cycle or Cq (the number of cycles where 
the fluorescence increases above background) mean for the two values and for the 
values of the housekeeping gene for each sample, were imported into the 
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QIAGEN RT2  profiler PCR array data analysis, version 3.5 website 
(SABiosciences, a QIAGEN company) 
(http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php), to obtain fold 
change calculations.  The sample with the lowest Cq mean was used to set the 
baseline from which fold change calculations were derived.  The measurement 
unit “fold change” refers to a fold-difference in quantity of DNA of any sample 
relative to the sample used as a baseline.   
 
3.7 Infectious center assays and fluorescent-focus assays 
Three different protocols were used for infectious center assays (ICA), and the 
different techniques did not appear to influence final results.  BL6 and BL6αGal 
cells, at a concentration of 2x105 to 3x105 cells/well, were placed in tubes in 1 mL 
MEM.  Another 1 mL of diluted virus, either HSV-2 or SINV AR339, at an MOI 
of 1.0, was then added the tube.  The cell-virus suspension was left to incubate for 
30, 60 or 90 minutes at 37° C, and tubes were shaken every 15 minutes.  At the 
end of each incubation point, virus was washed off twice by centrifugation with 3 
mL media each time.  At the end of each incubation period, cells were counted 
and then plated over a Vero cell monolayer in serial dilution (analogous to a 
plaque assay).   
 
Otherwise, BL6 and BL6αGal cells, at a concentration 3x105 cells/well, were 
plated in 12-well plates and left to adhere from 4 to 24 h.  Media were removed 
and virus was added in 500 μl at an MOI of 1.0 and left to incubate with cells for 
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30, 60 or 90 minutes at 37° C.  Plates were shaken every 15 minutes.  At the end 
of each incubation period, cells were harvested by dispersion with trypsin and 
washed twice by centrifugation.  Cells were then counted and overlaid on Vero 
cell monolayers in a serial dilution. 
 
Alternately, BL6 and BL6αGal cells, at a concentration 3x105 cells/well, were 
dispersed with trypsin and added to 96-well plates in 100 μl MEM.  Virus was 
then added to the wells in 100 μl and left to incubate for 30, 60 or 90 minutes at 
37° C.  Wells were gently pipetted every 15 minutes.  At the end of each 
incubation period, virus was washed off three times with 300 μl by centrifugation.  
Cells were then counted and overlaid on Vero cell monolayers in a serial dilution. 
 
For fluorescent focus-assays, BL6 and BL6αGal cells, at a concentration of 2x105 
to 3x105 cells/well, were seeded in 6-well plastic plates and left to adhere from 4 
to 24 h prior to infection.  At time of infection, media were removed and replaced 
with 1mL of complete MEM.  Either TE12-GFP or HSV-1GFP virus was diluted 
to an MOI from 0.01 to 1.0 in MEM, added to the cell monolayers, and left for 
adsorption periods from 15 to 180 minutes for adsorption assays at 37° C.  
Culture fluid with unabsorbed virus was removed, and cells were washed twice by 
pipetting and were re-fed with 2mL MEM.  The infection was left to run from 7 to 
48 h.  At the end of each time point, infected monolayers with GFP viruses were  
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observed using a Nikon Eclipse fluorescence microscope, and the images were 
analyzed with NIS-Elements Advanced Research imaging software; alternatively, 
cells were harvested by dispersion with trypsin and analyzed by FACs analysis. 
 
3.8 Blocking assays 
For blocking using the anti-Gal antibody, M86, 5x105 cells/well were seeded in 6-
well plates.  Cells were left to adhere to plates from 5 to 24 h in 2 mL of MEM.  
Media were removed and antibody was then added at different concentrations, 
from 1:5 to 1:100, in 1 mL of MEM.  Plates were left in the 37°C incubator for 60 
minutes and then 
SINV S.A.A.R86 or HSV-2, at an MOI of 0.1, in 100 μl MEM, was added to 
cells.  Cells were harvested using trypsin and washed by centrifugation, and then 
were plated over Vero monolayers. 
 
For blocking with liposomes (acquired from Dr. Uri Galili at the UMMS), 2x105 
plaque-forming units (PFU) of SINV TE12-GFP virus in 50 μl media were added 
to a solution of 1 μl or 2 μl of αGal-liposomes or control liposomes in a 50 μl 
suspension (total volume of 100 μl).  The virus-liposome mixtures were incubated 
at 4° C for 1 h.  The mixture was then added to 2x105 BL6 or BL6αGal cells 
suspended in 100 μl of MEM.  Cells were washed twice after a 2 h incubation 
period by centrifugation and plated in 6-well plates.  The infection was left for 9 h 
and cells were harvested and analyzed by FACs.   A second set of cells was left 
plated for examination at a later time point. 
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3.9 Enzymatic removal of αGal from cell surfaces 
To remove surface αGal from BL6αGal cells, 2x105 cells/well were added to 96-
well plates or to 2 mL tubes, in 100 μl of a phosphate buffered saline (PBS) 
solution.  BL6 were treated in parallel as controls. The PBS solution was adjusted 
to pH ranging from 6.0 to 7.0.  The enzyme is most efficient at pH 6.0, but cells 
do not fare well for too long.  At pH 7.0, the enzyme is less efficient and cells 
(although seemingly more healthy in their environment) must be treated for an 
extended period of time.  The pH levels of 6.2 and 6.4 worked best for this assay.  
The α-galactosidase from green coffee bean (Sigma-Aldrich) was added to cells at 
varying concentrations, from 1:4 (25 μl) to 1:25 (4 μl), in a total of 100 μl PBS 
solution.  The enzyme is specific to αGal and cleaves off the terminal 
disaccharide from glycoproteins and glycolipids on the cell surface.  Cells were 
incubated with enzyme for 60 min at 25°C or room temperature and shaken every 
15 minutes.  Cells were then washed twice by centrifugation.  One set of cells was 
tested directly after treatment for αGal expression using anti-Gal and analyzed by 
FACs.  SINV TE12-GFP virus was diluted to an MOI of 1.0 and added to the 
second set of cells in 96-well plates or 2 mL tubes in 100 μl.  Cells and virus were 
incubated for 60 min and then were washed twice by centrifugation.  Cells were 
then seeded in 6-well plates and the infection was left from 6 to10 h.  Cells were 
then harvested and fixed for FACs analysis.  
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3.10 Disruption of the GT gene using RNAi 
Four siRNA clones were purchased from QIAGEN (FlexiTube GeneSolution 
GS14594 for Ggta1), each targeting a different region of the gene.  siRNA clones 
were tested individually, or in combination, to observe if any single one or 
combination was especially effective in disrupting enzyme production.  BL6αGal 
cells were seeded in 12-well plates at concentrations of 2x104 cells/well to 6x104 
cells/well.  Each clone was tested at two concentrations, 5nM (0.3 μl) or 10nM 
(0.6 μl) mixed with 4 μl transfection reagent in a total of 100 μl incomplete MEM 
(no FCS or antibiotics).  The mixture was slightly vortexed and let stand for 
approximately 10 minutes for the reaction to occur.  Next, 100 μl of each clone 
mixture was added to freshly seeded cells (within 10 mins of seeding) in 500 μl 
MEM.  The mixture was added drop-style and distributed thoroughly throughout 
each well.  Cells were gently rocked and incubated in a 37° C incubator.   
Cells were analyzed at various time points, from 20 to 66 h pi.  As a control, 
fluorescently labeled Cy3-siRNA was utilized to ensure the BL6αGal cells were 
permissive of siRNA transfection. 
 
3.11 Addition of αGal molecules to host cell membranes using FSL Galili 
constructs 
Vero cells, which do not express αGal, were used in these experiments as the 
TE12-GFP virus replicates very well in this cell line.  Cells at a concentration of 
2x105 cells/well were added to 96-well plates, or 2 mL tubes, in 100 μl of neutral 
PBS.  FSL-Galili(tri) and control FSL-Biotin (Sigma-Aldrich) constructs are 
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composed of three fragments: a lipid, a spacer molecule and a functional 
component.  For these experiments, an αGal disaccharide or a Biotin molecule, 
used as a control, constituted the functional component of the construct.  These 
constructs insert themselves into cell membranes via the lipid segment of the 
construct and remain there for the lifetime of the cell.  Either FSL-Galili(tri) or 
FSL-Biotin at various concentrations, from 1:4 (25 μl) to 1:100 (1 μl), were added 
to Vero cells in 100 μl PBS.  The mixture was incubated from 60 -120 min and 
then washed twice with PBS.  One set of samples was used immediately after FSL 
treatment, to test for αGal expression by anti-Gal binding and for Biotin 
expression by fluorescently labeled streptavidin.  SINV TE12-GFP virus at an 
MOI of 1.0 in 100 μl of lipid-free media (incomplete MEM) was added to the 
second set of samples, and samples were incubated for 60 min in the 37° 
incubator.  The virus was then washed off twice by centrifugation, and 6-well 
plates were seeded with cells.  Cells were harvested between 6-10 h pi and fixed 
for FACs analysis. 
 
3.12 HSV-2 infections in adult male mice and γ-irradiation 
Male GT KO and C57BL/6J (WT B6) mice from 8 to 19 weeks of age were used 
in various experiments where no γ-irradiation was administered. Mice were 
inoculated intraperitoneally (i.p.) with 3.75x105 PFU or 5x105 PFU of HSV-2.  
Infected mice were examined daily for physiological or behavioral changes and 
sacrificed by cervical dislocation at 3, 4 and 5 days post infection.  Fat pad, spleen 
and liver were harvested and examined for signs of pathology, such as increase in 
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organ size or the formation of lesions.  Virus from organ suspensions was titrated 
by plaque assay on Vero cell monolayers.  For in vivo HSV-2 infections with γ-
irradiated animals, male GT KO and WT B6 mice between the ages of 8 and 14 
weeks received 9-11Gy.  Immediately after irradiation, mice were inoculated i.p. 
with 3.75x104 PFU of HSV-2.  Infected mice were observed and sacrificed as 
described above at days 2, 3, 4, 5 and 6.  Organs were harvested, examined, and 
titrated as described previously. 
 
3.12.1 HSV-2 infections of genetically crossed male mice 
For irradiation experiments, WT- crossed (F1 x WT) and KO- crossed (F1 x KO) 
male mice, aged approximately 12 weeks, were exposed to 10Gy of γ-irradiation, 
and immediately after, were inoculated i.p. with 8.5x105 PFU of virus.  Infected 
mice were examined daily for physiological or behavioral changes and sacrificed 
by cervical dislocation at day 6 pi.  Livers were examined for pathology such as 
lesions, and both liver and brain were homogenized for titration of virus.  The 
phenotype (αGal expresser or non-expresser) of genetically crossed mice was not 
known; therefore, blood was taken at time of harvest via heart punctures, to 
analyze for αGal expression of lymphocytes using BSl. 
 
3.13 HSV-1 infections 
 
For HSV-1 experiments, male and female GT KO, WT B6 and crossed mice (F1, 
F1xKO) of 4 weeks of age were used.  Mice were inoculated intranasally (i.n.) 
with 1.8x104 PFU in 20 μl.  Infected mice were sacrificed by cervical dislocation 
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at days 1, 2 and 4 pi.  Lungs were harvested and virus from organ suspensions 
was titrated by plaque assay on Vero cell monolayers.  Blood was also taken by 
performing heart punctures, and utilized to test for αGal expression by BS lectin 
binding and analyzed by FACs. 
 
3.14 γMHV-68 infections 
Male and female KO, WT, F1 and F1xKO mice from 6-12 weeks of age were used 
in various γMHV-68 experiments.  Mice were inoculated i.p. with 3.5x103 PFU or 
5.5x103 PFU of HSV-2.  Because a productive infection lasts until about 10 dpi 
(Sunil-Chandra et al., 1992), animals were sacrificed by inhalation of CO2 at days 
4, 5, 7, 9 and 11 pi to observe the course of the infection.  Spleens were harvested 
and weighed at time of sacrifice and then prepped for molecular analysis.  Viral 
genomes were quantified with real-time PCR as described for in vitro 
experiments.  
 
3.15 SINV infections of adult mice and γ-irradiation 
For SINV infections, male and female GT KO and WT B6 mice aged from 8 to 9 
weeks were inoculated i.p. with 105 PFU of SINV S.A.AR86 in 200 μl MEM.  
Blood, spleen, fat pads, or brain was harvested at days 1, 2, 3 and 5 for titration of 
virus.  Additionally, 8-week old mice were γ-irradiated with 10Gy and inoculated 
with the same dose of virus.  Blood, spleen, liver and fat pad were harvested at 
day 6 pi.  
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3.16 SINV survival studies 
GT KO and C57BL/6J suckling mice were infected via different routes and doses 
of different SINV strains as follows: 1) 8-day old mice were inoculated intra-
cranially (i.c.) with 200 PFU AR339 strain; 2) 13-day old mice were inoculated 
subcutaneously (s.c.) with 1.68x103 PFU.  Different inoculation routes and ages 
were used to determine susceptibility to infection. Pregnant females were 
monitored for day of birth, but because births from GT KO and WT B6 pups were 
not synchronized to the day, infections of mice were staggered.  Entire litters 
(ranging from 3-8 pups) were infected when pups came of age, excluding runts.  
Two to three litters per mouse strain were used for each experiment at each dose, 
SINV strain, and age of infection.  Mice were weighed daily and monitored for 
symptoms of disease, including paralysis, lethargy and other possible signs of 
neurological involvement such as spasms and shaking.  Additionally, WT, KO, 
F1xKO and F1xWT suckling mice aged 8 days were inoculated i.c. with 200 PFU 
or 1.1x106 PFU of S.A.AR86 virus.  Brains were harvested at day 1 and day 2 pi 
for titration of virus. 
 
3.17 Statistical methods 
Survival data were analyzed by Log-rank (Mantel-Cox) test and Gehan-Breslow-
Wilcoxon survival test using GraphPad inStat software.  Analyses of individual 
HSV-2 in vivo experiments were done using GraphPad inStat Student’s t tests and 
chi-squares, and analyses of pooled experiments were completed using Minitab  
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Statistical software ANOVA mixed models with random assumption, factoring 
dose, age, and experimental trial differences. Significance was set at P of ≤0.05; * 
indicates a P of ≤0.05, ** a P of ≤0.005. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 4 
DIFFERENTIAL HOST SUSCEPTIBILITY TO VIRUSES IN VITRO 
 
4.1 Surface expression of αGal on experimental cell lines 
Experiments were performed using paired cell lines.  In each pair, one line 
actively expressed the GT gene and the other did not.  Figure 3a shows that the 
BL6 cell line did not react with anti-Gal (left panel), or bind BS lectin (right 
panel), which also reacts with αGal.  The population of bright BL6 cells stained 
with BSl (right shoulder of peak) may be due to the broader binding specificity of 
BSl compared to anti-Gal.  The BL6αGT line bound both anti-gal and BSl.  
Figure 3b shows that the SK cell line did not react with anti-Gal, but SK-GT cells 
bound it.  The fluorescence peak from anti-Gal-stained SK-GT cell lines is broad, 
indicating that there is variation in the quantity of αGal residues expressed on the 
surface of individual cells within the GT-positive population.  These data confirm 
cell surface expression of αGal on BL6αGT and SK-GT at the time of these 
experiments. This is an important issue, as continued passage of the cells can 
result in decreased expression over time. 
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Figure 3: Expression of αGal on paired BL6 and SK cell lines. Cells were stained 
with anti-Gal (IgM) or BS lectin (BSl-B4), both of which bind αGal. The light grey 
peak represents αGal-negative cells and the black peak represents that of αGal-
positive cells. BSl can bind αGal monomers, while anti-Gal requires multiple sites 
for binding. MFI is mean fluorescence intensity of entire cell population.  (A) BL6 
and BL6αGT cell lines stained with anti-Gal or BSL. (B) SK and SK-GT stained 
with anti-Gal. 
4.2 Viral growth kinetics in the presence or absence of α1,3GT gene in the 
host cell 
If GT activity is important in the course of viral infections, then viral replication 
should be contingent on whether or not host cells express GT.  Previously, 
preliminary work in the laboratory of Dr. Raymond Welsh had demonstrated 
differential growth kinetics with Sindbis AR339, HSV-1 and HSV-2 in the paired 
GT-modified human melanoma cell lines, the SK-N-MC pLXN (SK) (inactive 
αGT gene) and SK-N-MC clone 10 (SK-GT) (active αGT gene).  I also verified 
GT-dependent differential susceptibility of SK and SK-GT cells to these viruses 
during the course of this study.  Sindbis viruses preferentially grew in GT-positive 
cells whereas HSV-2 grew better in GT-negative cells (Table 2).  Although the 
SK and SK-GT cell lines had been similarly maintained and passaged, they had 
slightly different morphologies and growth kinetics.  SK cells consistently  
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established a uniform monolayer whereas SK-GT cells appeared to lose contact 
inhibition after multiple passages.  Because of this, it was important to verify 
these findings in other paired cell lines. 
TABLE 2: Replication of viruses in SK human melanoma cellsa 
a HSV and SINV viruses grown in either GT-positive or GT-negative SK cells were 
titrated on Vero cell monolayers. These results were completed with single samples, 
but are representative of between 2-4 experiments. 
b Titers shown were peak titers for that time course. MOI =1.0. Bolded numbers 
indicate the comparably higher titer. 
The majority of the research for this dissertation (including all in vitro 
experiments that follow below) was completed using the paired B6 mouse-derived 
melanoma cell lines, BL6 (GT-negative) and BL6αGT (GT-positive).  In culture, 
these cells were the most robust and were also the best matched in terms of 
growth and phenotype.  Various SINV strains, herpes viruses and other enveloped 
viruses were screened on these cells to observe differences in susceptibility.  
Table 3 shows representative data from infections on BL6 and BL6αGT 
indicating that several of the viruses screened (VSV, LCMV, PV, MHV, MCMV) 
grew equally well (as measured by titers from culture fluid) in both BL6 and 
BL6αGT lines.  Any variations in the growth of these viruses in the two cell lines 
that did occur, such as with MCMV, were inconsistent.  
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TABLE 3: Replication of viruses in B6 melanoma cellsa 
a Viruses grown in either BL6 or BL6αGT cells were titrated on Vero cell 
monolayers. Experiments were completed in duplicate and are representative of 
between 2-4 tests. 
b Titers shown were peak titers for that time course.  MOI for VSV and PV was 1.0
and 0.1 for LCMV and MHV.  
c - denotes no virus growth. 
Differences in replication between cell lines were consistently observed for all 
tested SINV strains (AR339, S.A.AR86, TR339, SVHR and TE12-GFP), HSV-1, 
HSV-1 GFP and HSV-2.  Notably, the SINV strains grew often to 10-20 fold 
higher titers in the presence of αGT, whereas the HSV strains grew often to 100-
fold higher titers in the absence of αGT (Figure 4).  SINV growth differences 
between cell lines were observable early in the time course—after a single round 
of viral replication (Figure 4b).  SINV-infected BL6αGT monolayers also 
exhibited more cytopathic effects (CPE) than BL6 cells.  BL6 cell monolayers, in 
contrast, were much more susceptible to HSV-1 and HSV-2 infections (Figure 4c) 
and exhibited greater CPE.  A third herpes virus, murine gammaherpes virus 68 
(γMHV-68), also replicated better in GT-negative cells (Figure 4c).  
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Figure 4: Growth kinetics of SINV and herpes viruses in B16 cell lines. Results are 
representative of >5 experiments for HSV and SINV and of 2 tests for γMHV-68. 
Virus was diluted to an MOI of 1.0 in MEM, added in 100 μl (SINV strains) or 400μl 
(herpes viruses) to the BL6 and BL6αGT monolayers, and left for an adsorption 
period of 60 minutes. (A) and (C) During time courses, culture fluid from cell 
monolayers were collected every 24 h for 72 h pi  (SINV AR339 and γMHV-68) or 
96 h pi (HSV 1 and 2). (B) For 12 h replication experiments, cell monolayers were 
infected with SINV viruses at an MOI of 0.1 and culture fluid was collected, starting 
at 12 h pi. 
To further test differential replication of γMHV-68 in the two cell types, time 
courses were completed using the BL6 and BL6αGal paired cell lines.  At various 
time points post infection, cell populations were harvested and DNA from cell 
populations was analyzed by real-time PCR.  Absolute quantification of viral 
 
copy number was not possible because no calibration standard was used.  Instead, 
relative quantity of DNA was standardized using a housekeeping gene, as 
discussed in Methods and Materials.  For each experiment, the sample with the 
lowest quantity of viral DNA was set as a baseline to compare the rest of the 
samples to.  The unit of measurement, “fold change”, refers to a fold difference in 
quantity of DNA of each sample to the quantity of the baseline sample.  At 24 h 
pi, the quantity of viral DNA in GT-negative cells was three times that of GT-
positive cells, and this difference was increased to almost 13-fold by 68 h pi 
(Figure 5, left graph).  It is of interest that there was the same relative amount of 
viral DNA present at 24 h and at 68 h pi in the infected BL6αGal cell population.  
In a separate experiment, at 48 h pi, there was approximately 1.8 times more viral 
DNA in the population of BL6 cells relative to the BL6αGal cells (Figure 5, right 
graph).  The relatively greater quantity of DNA found in GT-negative cells 
compared to GT-positive cells correlates with higher viral titers found in culture 
fluid from infected BL6 and BL6αGal cell populations.   
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Figure 5: Relative viral quantity in infected BL6 and BL6αGal.  Results are 
representative of two separate experiments completed in duplicate. Time courses 
were completed as previously described and infected cells were harvested for 
analysis at 24 and 68 h pi, or at 48 h pi.  Virus was used at an MOI of 1.0. Viral 
DNA was quantified using real-time PCR.  
In the systems studied here, related viruses behaved similarly during infections of 
each cell type.  Viral preference for expression or non-expression of αGT in host 
cells appears to be a general characteristic of certain viruses, and also appears to 
be virus-dependent but not viral-strain dependent.
4.3 Viral expression of αGal does not affect host-cell susceptibility to SINV 
and HSV strains 
Enveloped viruses incorporate host-cell carbohydrates onto their envelopes during 
egress from cells, and this in turn can affect interactions with subsequent host 
cells.  Various enveloped viruses, including SINV, acquire αGal after passages in 
mouse fibroblast L929 (αGT-positive) cells (Repik et al., 1994; Welsh et al., 
1998).  To determine whether viral infectivity on our two cell lines was affected 
by the presence of αGal on the virion, time course assays were completed on BL6 
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and BL6αGT cell lines with HSV-1 and 2 and with several SINV strains that had 
been propagated in L929 cells (designated SINVαgal, HSV-1αgal and HSV-
2αgal).  These SINVαGal virus strains still preferentially replicated in cells 
positive for αGT gene expression (Figure 6a), while HSV-1αgal and HSV-2αgal 
both preferentially grew in αGT-negative cells (Figure 6b).   
Figure 6: Growth kinetics of αGal expressing viruses in BL6 cell lines. Results are 
representative of 2 separate experiments.  SINV and herpes viruses were 
propagated in αGal-positive L929 cells to produce virions expressing αGal. Time 
courses were completed as previously described.  SINV(αgal) was used at an MOI of 
0.1 and or HSV(αgal) at an MOI of 0.01.  Culture fluid was harvested every 12 h for 
48 hpi (SINV(αgal)) or  every 24 h for 72 h pi (HSV(αgal)).  
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Further, the αGal-expressing SINV S.A.AR86 virus replicated to similar levels to 
non-αGal expressing virus when used at the same MOI (Table 4).  These results 
indicate that host-cell susceptibility to various SINV strains and to HSV 1 and 2 is 
affected by host-cell differences in αGT gene expression but not by variable αGal 
expression on the viruses. 
TABLE 4: Replication of S.A.AR86 and S.A.AR86(αgal) in BL6 cellsa  
a BL6 and BL6αGT were infected with SINV S.A.AR86 expressing or not expressing 
αGal on its envelope at an MOI of 0.1.  Experiment was done in duplicate. Results 
are representative of a single experiment, and titers are consistent with results from 
other time courses with S.A.AR86 at similar MOI. 
b The titers shown are peak titers during a 48 h time course.  Higher titers are 
bolded.  
4.4 Level of viral replication correlates with the proportion of infected cells 
in the population 
Susceptibility to viral infections that is dependent on αGT-expression should be a 
general characteristic of the entire cell population.  High viral titers as measured 
from culture fluid, however, could indicate two different phenomena: 1) many 
infected cells producing moderate levels of virus or 2) a subpopulation of infected 
cells producing high amounts of virus.  In order to investigate whether the 
amounts of virus in culture fluid correlated with the fraction of infected cells in 
the population, we used SINV and HSV-1 recombinants that express a green 
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fluorescent protein (SINV TE12-GFP and HSV-1 GFP ICP8 mutant) during 
replication, and we performed time course assays on BL6 and BL6αGT cells.  
HSV-1 GFP has reduced replication potential due to an ICP8 gene mutation that 
interferes with late gene expression, but not with its ability to initiate infection; 
therefore, differences in virus yields between cell types can still indicate a 
difference in cell susceptibility to infection.  Further, GFP is expressed as a 
delayed early gene product, and so fluorescence in host cells is a useful measure 
of a first round of infection.  Infected cells were directly measured via FACs, and 
virus from culture fluid was quantified by plaque assay.  As seen with wild type 
strains, SINV TE12-GFP replicated better in BL6αGT cells (Figure 7a), whereas 
HSV-1 GFP replicated better in BL6 cells (Figure 7b).  Under fluorescence 
microscopy, GFP SINV- infected BL6αGT cell monolayers had relatively large 
areas of fluorescing cells compared to SINV-infected αGT-negative cells (Figure 
7c).  Conversely, HSV-1-infected αGT-positive cell monolayers exhibited 
relatively small foci of fluorescing cells compared to HSV-1-infected BL6 cells 
(Figure 7d).  Time course studies using FACs analysis showed that a substantially 
greater fraction of SINV-infected GT-positive cells expressed GFP (Figure 7e), 
compared to a small subpopulation of BL6 cells, even after multiple rounds of 
replication.  In contrast, a much greater proportion of HSV-1-infected BL6 cells 
expressed GFP, and only a small fraction of αGT-positive cells were GFP positive 
for the duration of the time course (Figure 7f).  Comparable mean fluorescent 
intensity (MFI) levels of GFP were observed across both cell lines during SINV 
and HSV infections (Figures 7g and 7h), suggesting that once cells are 
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productively infected, virus is synthesized at similar levels in both cell lines.  
These data suggest that differences in viral replication between host cell types are 
due to differential success in virus establishing a productive infection. 
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Figure 7: Replication of GFP viruses in BL6 cell lines.  Time courses on BL6 and 
BL6αGT cells were performed as previously described.  Results with SINV GFP are 
representative of >5 experiments and for 3 experiments with HSV GFP.  SINV 
TE12-GFP was used at an MOI of 1 and HSV-1 GFP at an MOI of .1. (A) Culture 
fluid was collected from SINV-infected monolayers for titration every 6 h for 26 h pi 
or (B) from HSV-infected monolayers every 12 h for 48 h pi. (C) and (D) Infected 
monolayers were observed under a fluorescence microscope to visually monitor 
infection and (E) and (F) cells were harvested for FACs analysis. (G) and (H) Mean 
fluorescence intensity of GFP expressing cells was measured via FACs Diva 
Software. 
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4.5 Differences in host-cell susceptibility are evident early after viral 
infection  
Using GFP viruses, the success of an initial infection in host cells can be 
measured by FACs analysis, as infected cells will fluoresce.  Cells were incubated 
with either SIN GFP or HSV-1 GFP for varying time periods, and infected cells 
were harvested prior to completion of a first round of replication—thus measuring 
initial infection levels—and analyzed via FACs.  In HSV-1 GFP assays longer 
adsorption time resulted in a small increase of infected BL6 cells, but the 
infection on BL6αGT monolayers was almost negligible (Figure 8a).  In SINV 
GFP assays, longer adsorption time resulted in higher fractions of αGT-positive 
infected cells, but not of αGT-negative cells; infection levels in BL6 cell 
populations did not increase with adsorption times longer than 120 minutes 
(Figure 8b).  Additionally, it is of interest that following multiple rounds of 
replication (Figure 8c) the proportion of GFP SINV-infected cells in the BL6 
population declined.  This was not a result of lysed cell monolayers, as at 36 h pi 
the BL6 cells appeared more intact than BL6αGT cell monolayers (Figure 8d) and 
only focal areas exhibited cytopathic effects; the majority of the monolayer 
simply appeared to resist infection.  This could suggest heterogenicity of the BL6 
cell population with respect to permissivity to SINV infection, whereby some 
cells are permissive to infection and others are not.  This could also indicate that 
viral infectivity declines after a first round of replication, a possible consequence 
of defective interfering (DI) particles.  Along with infectious particles, Sindbis 
virus can generate DI particles that disrupt the replication cycle (Shenk and 
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Stollar, 1973).  However, low MOIs were often used for SINV infection assays to 
reduce the possibility of this occurrence.  Additionally, reduced infectivity was 
not a result of multiple rounds of infection, but was noticeable during the initial 
infection.  This could suggest that DI particles are present in the viral stock, yet 
interfererence did not appear to be an issue for infections on Vero or BL6αGT 
cells.  In either case, the mechanism by which infection is limited in BL6 cells 
appears to occur early in virus-host cell interactions. 
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Figure 8: Virus adsorption to BL6 and BL6αGT cell lines. Results are 
representative of >5 experiments with SINV GFP and 3 for HSV GFP.  Virus was 
diluted to an MOI of 1.0 (SINV TE12-GFP) or MOI of 0.1 (GFP HSV-1) in MEM, 
and added in 100 μl to the BL6 and BL6αGT monolayers for varying periods of 
time. Culture fluid with unabsorbed virus was removed after each incubation end 
point, and cells were washed twice with media and re-fed with 2 mL MEM.  At 
harvest, cells were prepared for FACS analysis. (A) GFP HSV-1 was incubated with 
cells for 30, 60 or 90 minutes and monolayers were harvested at 18 h pi, prior to one 
round of replication. (B) GFP SINV was incubated with cells between 15 to 180 
minutes and cells were harvested between 7 to 10 h pi, prior to one round of 
replication. (C) GFP SINV was incubated with cells for 60, 120 or 180 minutes and 
cells were harvested at 35 h pi, after multiple rounds of infection. (D) GFP SINV 
infected cell monolayers approximately 36 h pi under light microscopy. 
4.6 Testing restriction of SINV infection by blocking αGal sites on host cells 
Fluorescence focus-assays indicate that differences in viral growth correlate with 
the successful infection of a host cell.  Host-cell glycans are commonly utilized by 
viruses during the entry process; as such, the α-galactosyltransferase product αGal 
could play a role in facilitating or restricting infection.  To explore the possible 
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role of αGal in viral entry, αGal sites were blocked using the anti-Gal antibody 
(ab), M86.  BL6 and BL6αGal cell monolayers were treated with the M86 ab at 
varying dilutions and were then inoculated with the SINV S.A.AR86 strain, which 
has shown preference for preferentially replicating in αGal positive cells.  In cell 
cultures without ab treatment, SINV preferentially replicates in cells expressing 
αGal (Figure 9).  For BL6 cell populations, the relative fraction of infected cells 
does not change whether it is untreated or treated with M86.  In contrast, the 
fraction of infected BL6αGal cells treated with 1:10 dilution of anti-Gal is slightly 
reduced (Figure 9, left graph).  In a second experiment (Figure 9, right graph), the 
fraction of BL6αGal cells treated with 1:50 dilution of M86 drops significantly 
compared to the untreated, SINV-infected cells.  When the concentration of anti-
Gal treatment is reduced, the fraction of infected BL6αGal cells increases, but is 
still lower relative to the fraction of untreated, SINV-infected cells (Figure 9, right 
graph).  These data must be interpreted with caution, however, for two reasons: 1) 
the standard deviation for experimental values completed in duplicate is large, 
which indicates a large margin of error and 2) additional experiments to confirm 
these observations were not successful.  In several experiments, the antibody 
agglutinated cells in monolayers, or in suspension, during the incubation period 
and experiments were terminated.  Overall, although some results may indicate 
that blocking αGal sites restricts SINV infection (at least with the S.A.AR86 
strain), the data are not sufficiently reliable to confirm this phenomenon. 
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Figure 9: Blocking host cell αGal sites with anti-Gal. Anti-Gal antibody was used to 
bind to αGal sites on BL6 and BL6αGal monolayers.  Antibody was added to cell 
monolayer at various dilutions and left for 60 min, then washed off. Virus was then 
added at an MOI of 0.1 and left for 60 min.  Cells were removed by dispersion with 
trypsin and plated over Vero monolayers in serial dilution.  
Additional methods to block glycan-virus interactions were attempted, including 
using free αGal in solution acquired from Dr. Uri Galili at the UMMS.  The αGal 
solution was incubated with SINV AR339 and then the αGal-virus solution was 
added to BL6 and BL6αGal monolayers.  The rationale was that if SINV binds 
αGal residues on host cells, then it may also bind free αGal molecules in solution, 
which would then prevent binding to the host cell.  Unfortunately, the cell 
monolayers were damaged by the treatment, so this strategy was not effective. 
A third blocking method was the use of liposomes that contained αGal epitopes in 
the membrane and control liposomes derived from KO pig red blood cells (both 
acquired from Dr. Uri Galili).  Liposomes were incubated with virus, and the 
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liposome-virus solution was added to BL6 and BL6αGal monolayers.  The 
function of αGal liposomes in these experiments was analogues to free αGal in 
solution described above.  However, the cells reacted poorly to the treatment 
(Figure 10).  Similarly to anti-Gal treatment, the liposomes tended to agglutinate 
the cells in culture.  At 9 h pi, cells from some wells were harvested and fixed for 
FACs analysis, and cells from other wells were left for later examination.  After 
24 h post-treatment, the cell monolayers began to recover and returned to their 
normal morphology.  Despite this, due to the unhealthy morphology of cells 
directly after treatment, experiments were terminated. 
Figure 10: αGal liposome treatment of BL6 and BL6αGal cells.  Monolayers at 2 h 
post-treatment with the liposome. 
4.7 Enzymatic removal of αGal from host cells  
Results from blocking experiments were inconclusive due to problems with 
replicating results or with reagents that were toxic to cells.  However, the role of 
αGal in viral infections could still be examined by removal of the sugar from the 
surface of host cells.  BL6 and BL6αGal cells were treated with the green bean α-
galactosidase enzyme that cleaves the terminal Gal residue on the cell’s surface.  
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Under the right conditions (discussed in methods), the enzyme was very efficient 
at removing surface αGal from cells without damaging cells (Figure 11), and αGal  
residues were not detected on BL6αGal cells at normal levels by 6 h post 
treatment.  The unusually high MFI for the negligible αGal-positive population in 
the BL6 sample was possibly due to non-specific binding. 
 
Figure 11: Enzymatic treatment of BL6 and BL6αGal cells.  Cells were treated with 
5 μl of enzyme in 100 μl of pbs at pH 6.2 for 45 minutes.  Cells were stained for αGal 
expression using the anti-gal ab M86. MFI is mean fluorescence intensity of entire 
cell population. 
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Once the removal of αGal residues was confirmed via FACs analysis, cells were 
infected with SINV TE12-GFP.  Infections were left between 6-10 h, and infected 
cells were harvested prior to a first round of replication—thus measuring initial 
infection levels—and analyzed via FACs.  As expected, a greater proportion of 
the BL6αGal cell population was infected with SINV compared to BL6 cells 
(Figure 12a, left column).  Green bean α-galactosidase is most efficient at low pH 
(6.0-7.0).  To control for any effects of the harsh conditions on cells, infections 
were performed in both normal cell culture media and also in low pH solution.  
Incubation of cells in either low pH solution or MEM did not appear to affect 
susceptibility to infection for either cell type (Figure 12a, right column).  Removal 
of αGal from BL6αGal cells increased the proportion of cells infected by SINV 
TE12-GFP (Figure 12b, top panel).  In various experiments, infection levels 
ranged between 2 to 6-fold lower in treated cells compared to untreated cells.  
Surprisingly, treatment with α-galactosidase also resulted in reduced levels of 
infection for BL6 cells compared to untreated cells (Figure 12b, bottom panel).  
The reduced infection observed in BL6 cells could indicate that α-galactosidase 
also interacts with another component on the cells that is involved in 
susceptibility to SIN infection.   Overall, treatment of cells with the galactosidase 
did not identify a role for αGal in viral infections.  More work is needed to 
understand the dynamics of αGal cleavage in BL6 cells and SINV infection. 
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Figure 12: Infection of enzymatically treated cells with SINV TE12-GFP.  Bl6 and 
BL6αGal cells were treated with 5 μl of α-galactosidase in 100 μl of PBS at pH 6.2 
for 45 minutes.  Cells were then infected with virus at an MOI of 1.0 and infection 
ran for 7 h. As a control, cells were infected in MEM media and also in low pH 
solution. Cells were harvested by dispersion using trypsin and analyzed by FACs. 
MFI is mean fluorescence intensity of GFP-positive cells.  
These experiments also showed that the MFI of infected BL6 cells is considerably 
higher than infected BL6αGal cells (Figure12b).  This phenomenon was not 
observed in experiments completed with the first lot of virus propagated in Vero 
cells, but was noticed after several passages (approximately 3) in Vero cells 
where viral stocks were grown.  MFI is used as a relative measure of viral 
replication within a cell; brighter cells have more viral replication and thus 
express greater amounts of GFP.  For BL6 cells, that could suggest that although 
few cells become infected in the population, the virus replicates very well once  
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inside the cell.  The relatively lower viral output, measured from culture fluid, 
could result from the initial low-level infection in the population or could indicate 
that viral egress is restricted in the infected cell subpopulation. 
 
It was also possible that the two cell types had different IFN-induced antiviral 
activity, and therefore responded to viral infection differently.  Sindbis virus is 
sensitive to antiviral effects of IFN α/β.  The virus replicated well in the BL6 
cells, but infection levels were low compared to BL6αGal.  If BL6 cells produced 
greater amounts of IFN early during infection, it could have protected the rest of 
the population from becoming infected, and thus explain the greater proportion of 
infected BL6αGal cells.  An inhibition assay for interferon was performed in 
order to measure IFN in culture fluid of SINV TE12-GFP infected BL6 and 
BL6αGal cells.  In some assays, both cell lines had comparable levels of IFN 
(Figure 13, left graph) but in other assays, the BL6αGal cell population produced 
more IFN than the BL6 population (Figure 13, right graph).  It is possible that 
higher levels of viral replication in the BL6αGal cell population induced higher 
levels of interferon production.  It is clear, however, that the lower proportion of 
infected cells in the BL6 population was not a result of a relatively more robust 
IFN response. 
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Figure 13: Assay for interferon production in the BL6 and BL6αGal cell lines.  Cells
were infected with SINV TE12-GFP and culture fluid was harvested from infected 
cells from 6 to 36 h pi.  Virus in samples of culture fluid was then inactivated under 
UV light to be used in the VSV protection assay.  
4.8 Addition of αGal terminal residues to GT-negative host cells  
Attempts to understand the role of αGal in viral-host interactions by blocking or 
removal of the surface sugar or knockdown of GT activity were not successful.  
An alternative method was to add the carbohydrate molecule to GT-deficient host 
cells and examine its effects on viral infections.  The FSL (function, spacer, lipid) 
construct system was a good candidate for these experiments because the 
constructs are composed of three parts: a functional terminal end, a spacer 
molecule and a lipid molecule.  The lipid portion can insert itself into membranes 
(be it cellular or viral) and the functional portion is exposed in the extracellular 
space.  The functional unit of the FSL-Galili(tri) construct contains the 
Galα1,3Galβ1,4GalCNAc molecule.  The BL6 cell line seemed a good candidate 
for these experiments, but these cells were not very receptive to the FSL 
constructs.  A relatively high quantity of the reagent was necessary to produce 
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only a small proportion of αGal-expressing cells in the population.  Instead, Vero 
cells that derive from Chlorocebus sp. and do not have a functional GT gene, 
were utilized.  Cells were treated with the FSL-Galili(tri) to express αGal residues 
on the surface.  Figure 14a shows that a vast majority of Vero cells was made to 
express αGal, although at relatively low levels.  Treated and untreated Vero cells 
were then used to examine viral-host cell glycan interactions as both cell types 
were identical, but for the expression of terminal αGal.  Because the addition of 
an exogenous molecule to the host cell might have unforeseen effects that can  
skew findings, a control FSL construct was used: the FSL-Biotin, which has a 
Biotin molecule as the functional portion of the construct.  The control construct 
also integrates itself well into the cell membrane (Figure 14b).    
Figure 14: FSL treatment of Vero cells for SINV TE12-GFP infection.  Cells were 
incubated with either FSL Galili(tri) or control FSL-Biotin at a concentration of 1:4 
for 60 min and then infected with virus at an MOI of 1.0.  At 2.5 h post treatment, 
cells were tested for expression of αGal or Biotin using FACs. (A) Cells treated with 
FSL-Galili(tri) were tested for successful insertion using anti-Gal, M86 and (B) Cells 
treated with FSL-Biotin were tested for successful insertion using fluorescently 
labeled streptavidin. MFI is mean fluorescence intensity of entire cell population. 
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Vero cells treated with both constructs were infected with the GFP SINV TE12 
strain and cells were harvested prior to a second round of replication to look at the 
initial infection cycle.  Compared to untreated Vero cells infected with the virus 
(Figure 15a), the proportion of FSL-Galili(tri) treated cells that became infected 
increased slightly, and the proportion of FSL-Biotin treated cells that became 
infected dropped slightly (Figure 15b).   Strangely, when the concentration of FSL 
constructs is reduced (resulting in fewer constructs inserted into the host cell 
membrane), the infection level of FSL-Galili(tri) treated cells is slightly reduced, 
but infection level of FSL-Biotin treated cells  is increased (Figure 15c).  Other 
experiments demonstrated this same phenomenon.  Cells treated with higher 
concentrations of FSL-Galili(tri) resulted in more significant increases in TE12-
GFP infection; but cell treatment with low concentrations of FSL-Biotin also 
resulted in an increase in TE12-GFP infected cells.  These data suggest that the 
constructs do have a moderate effect in viral-host cell interaction; however, it is 
not specific to αGal residues. 
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Figure 15: Infection of FSL-treated Vero cells with SINV TE12-GFP.  Cells were 
incubated with either FSL Galili(tri) or control FSL-Biotin and were infected with 
TE12-GFP at an MOI of 1.0. (A) Control: virus infected cells without FSL 
treatment. (B) Cells treated with FSL-Galili(tri) or FSL-Biotin at a concentration of 
1:4 and infected with virus. (C) Cells treated FSL-Galili(tri) or FSL-Biotin at a 
concentration of 1:10 and infected with virus. 
To examine if FSL-constructs affected the course of other viral infections, Vero 
cells treated with the constructs were infected with HSV-1 GFP.  Due to low 
quantity of available reagent, cells were treated with a more dilute mixture, and 
accordingly, a decrease in αGal expression on treated cells was observed (Figure 
16a).  Infected cells were harvested prior to a second round of replication in order 
to observe an initial infection cycle.  No difference was observed in the level of 
infection between treated and untreated Vero cells, although it is possible results 
were skewed by reduced αGal expression on treated cells (Figure 16b).  However, 
repeats of this experiment resulted in a greater proportion of cells incorporating 
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αGal molecules, but differences in infection levels between treated and untreated 
cells were still not observed.  Overall, addition of αGal to GT-deficient host cells 
did not identify a role for αGal in viral infections. 
Figure 16: FSL treatment of Vero cells for HSV-1 GFP infection.  Cells were 
incubated with either  FSL Galili(tri) of 1:10 for 60 min and then infected with 
HSV-1 GFP at an MOI of 0.2.  (A) At 2 h post treatment, cells were tested for 
expression of αGal using anti-Gal, M86. MFI is mean fluorescent intensity of entire 
cell population (B) Cells were harvested 20 hpi and analyzed by FACs for GFP 
expression.   
In vitro experiments showed that the presence or absence of the GT gene in a host 
cell plays an important role in the course of viral infections. The viral kinetics of 
various herpes viruses and Sindbis virus strains seem to be dependent on the state 
of GT expression in the host.  Herpes viruses preferentially replicate and infect 
GT-negative host cells, and SINV strains have greater infectivity in GT-positive 
cells.  Host cell susceptibility to infection appears to be determined by an event 
early in virus-cell interaction.  Enzymatic removal of αGal from cell surfaces may 
indicate that the presence of αGal plays a role in facilitating infection by SINV; 
however, the mechanism by which susceptibility is affected could not be
established.  
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CHAPTER 5 
DIFFERENTIAL HOST SUSCEPTIBILITY TO VIRUSES IN VIVO 
 
5.1 T KO mice are more susceptible than WT mice to HSV-2 infections 
The role of the GT gene or αGal expression must be relevant in vivo in order to 
have implications for primate evolution.  To test whether our in vitro data could 
be corroborated in vivo, we used C57BL/6J (WT B6) mice that naturally express 
the GT gene and GT knockout mice (GT KO) that lack it.  Mice aged 8 to 19 
weeks were inoculated by the intraperitoneal route with different doses of HSV-2.  
From i.p. inoculations, HSV-2, which is not highly pathogenic in B6 mice, 
spreads via blood to visceral organs.  Spleen, liver and visceral fat pads proximal 
to the injection site were harvested at various days post infection to quantify virus.  
At day 3 pi, viral loads from splenic suspensions were often higher in KO mice 
compared to the WT, but this was not always statistically significant.  However, 
virus accumulated significantly more in livers of GT KO mice compared to livers 
of age-matched WT B6 mice, regardless of initial inoculum.  Virus was detected 
in a greater proportion of KO mice (83.4%) compared to WT mice (45.5%)  (x2= 
5.9, df = 1, P < 0.02), and macroscopic hepatic lesions commonly associated with 
HSV-2 infections following i.p. inoculation (Mogesen et al., 1974; Mogesen, 
1977) were more frequently observed in KO mice (27.7%) than in WT mice 
(5.5%).  Independent experiments did not always show statistically significant 
differences in liver viral load between the two mouse types, but analysis of 
variance (ANOVA) of titers from pooled experiments demonstrated significant 
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differences (F=8.36; df=1; p=.007).  Additionally, by day 4 pi, virus was detected 
in a significantly greater proportion of livers from KO mice (88.2%) than WT 
mice (35.3%) (x2 = 10.09, df = 1, P < 0.002).  Viral load was also significantly 
higher in KO mice compared to WT mice, irrespective of age of mouse or viral 
dose administered (Figure 17a and b), and a greater proportion of KO mice 
exhibited hepatic necrosis (29.4%) compared to WT mice (11.8%).  By day 5 
post-infection, KO and WT mice had largely cleared the infection from all organs 
tested.  These data show differences in resistance to HSV-2 between KO and WT 
mice, reflected in the amount of virus isolated from liver and from the level of 
hepatic necrosis observed. 
Figure 17: HSV-2 infections of KO and WT B6 mice.  Mice were inoculated i.p. with 
HSV-2.  Organs for titration (PFU/organ) from mice were harvested at days 3,4 and 
5.  In figure, wo = weeks old.  (A) Mice aged 8-weeks of age were inoculated with 
5x105 PFU in 400μl media or (B) of 9, 11 or 19 weeks of age were inoculated with 
3.75x105 PFU in 300μl media.  
 
The GT KO and WT B6 mouse lines, although genetically similar, could present 
differences in their immue response to infection.  To ensure that observed 
differences in susceptibility to HSV-2 were not an artiface of immune system 
differences between the two mouse lines, mice were given a high dose of gamma-
irradiation directly prior to infection.  Replication of HSV-2 was considerably 
enhanced in the spleen and livers of these immunocompromised KO mice but 
only slightly improved in WT mice.  At day 2, the virus was barely detectable in 
spleens of WT mice, but KO mice had mean viral titers up to 80-fold higher 
(Figure 18, left panel).  By day 5 post-infection, all KO mice exhibited numerous 
large focal necrotic lesions and elevated viral load in livers (Figure 18, right 
panel).  In contrast, only a few WT mice presented small hepatic lesions and 
relatively lower (or undetectable) viral titers.  Thus, the presence of GT confers a 
level of resistance to HSV-2 infection in mice. 
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Figure 18: HSV-2 infections of γ-irradiated mice. Mice were aged 8 to 14 weeks were 
inoculated with 3.75x105 PFU of HSV-2 in 300 μl media.  Organs for titration 
(PFU/organ) were harvested at days 2,3,4,5 or 6. In figure, wo = weeks old. 
5.2 Genetic background of GT KO mice and susceptibility to HSV-2 
GT KO mice were created in a DBA/2, 129Sv and B6 background.  Despite being 
backcrossed into the C57BL/6J background over multiple generations, it is 
important to ensure that any genotypic differences between KO and WT mice do 
not influence response to HSV-2 infection.  In preliminary tests to determine this, 
WT, KO and various mouse crosses (F1, F1xWT, F1xF1, F1xKO) of varying ages 
were γ-irradiated with 10Gy and immediately infected with HSV-2.  αGal 
expression was tested from peripheral blood samples using anti-Gal antibody.  By 
BS lectin binding, expression of αGal in the cell population of GT KO mice is 
close to zero, while in WT B6 mice, it can range between 80-95% (Figure 19).  It 
should be noted that in the heterogeneous population derived from blood of WT 
B6 mice, there was no distinct separation between the population of expressers  
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and of non-expressers.  As in other tissues, αGal-expression likely occurs across a 
spectrum whereby different individual cells express different quantities of αGal 
on the surface. 
Figure 19: Expression of αGal on lymphocytes of KO and WT mice. Cells were 
stained with BS lectin (BSl-B4), which binds αGal monomers.  (Left panel) Cell 
populations derived from KO mice express practically no αGal on their surface, 
while (right panel) the majority of cells in the population derived from WT mice 
express different quantities of surface αGal.  MFI is mean fluorescence intensity of 
entire cell population.
To analyze the role of the GT KO genetic background in its susceptibility to 
HSV-2, age-matched F1 male mice that had been backcrossed with parental 
strains (F1xWT or F1xKO) were γ-irradiated with 10Gy and then infected i.p. with 
HSV-2.  Blood was collected and utilized for testing αGal expression with BS 
lectin.  Additional antibodies were included in fluorescence analysis to locate a 
homogenous population of lymphocytes, and limit factors that could influence the 
analysis (e.g., different cell types expressing different levels of αGal).  The 
congenic marker, Thy 1.2, revealed that there were very few lymphocytes in 
peripheral blood preps, potentially because gamma radiation had eliminated much 
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of the population.  Using the small Thy 1.2 subpopulation, individuals with very 
low αGal expression vs. high αGal expression were differentiated (Figure 20a).  
At day 6 pi, there were no statistically significant differences in mean viral titers 
from liver or brain suspensions of αGal-negative and αGal-positive individuals 
(Figure 20b).  The three αGal-negative mice with the highest viral load exhibited 
macroscopic hepatic lesions.  One αGal-positive mouse had light spotting on the 
liver but the corresponding viral titer was below the limit of detection.  Additional 
experiments with crossed mice were completed with a modified protocol, 
whereby blood was taken a week prior to infections to determine αGal status of 
the animal, as gamma-irradiation depleted the immune cell population used for 
αGal detection.  Unfortunately, in three separate experiments, KO and WT mice 
did not yield sufficiently high viral titers for proper analysis, even after viral 
inoculum was increased.  Although these results trend in the direction of previous 
findings which showed that KO mice developed greater pathology compared to 
WT mice, the observed differences in this experiment were not statistically 
significant.  Overall, these do not clarify whether the GT KO background plays a 
role in its increased susceptibility to HSV-2 infections. 
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Figure 20: HSV-2 infection of backcrossed male mice.  Mice of genetically crossed 
background, aged 12 weeks, were γ-irradiated and subsequently inoculated i.p. with 
8.5x105 PFU in 100μl media.  (A) αGal expression of lymphocytes from blood preps 
was tested using BSl. (B) Liver and brain were harvested at day 6 pi.   denotes 
large hepatic lesions. 
5.3 WT and GT KO mice are similarly susceptible to HSV-1 infections  
In vitro, herpes simplex type 1 exhibited preferential growth in cells that lacked 
GT activity.  WT B6 mice are highly resistant to HSV-1 infection via the i.p. 
route, but are susceptible if infected intranasally (i.n.) and quickly develop 
pneumonia (Adler et al., 1997).  In order to verify if in vitro findings translate to 
an in vivo system, males aged 4 weeks, were anesthetized and infected i.n. with 
1.8x104 PFU.  Numerous crossed mice were readily available for testing and were 
used in these experiments.  BS lectin was used to test for αGal expression in 
peripheral lymphocytes.  At day 1 and day 2 pi, there was no difference in mean 
viral titer from suspensions of whole lung between αGal-negative and αGal-
positive individuals (Figure 21).  By day 4 pi, both groups of mice appeared to be 
clearing the virus from lungs.  These results suggest KO mice do not have 
increased susceptibility to HSV-1 infections via the intra-nasal route, compared to 
their αGal-expressing counterparts. 
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Figure 21: HSV-1 infections of WT, KO and crossed male mice.  Mice, aged 4 weeks, 
were inoculated i.n. with 1.8x104 PFU in 20 μl.  Lungs were harvested at days 1, 2 
and 4. Day 1 results are representative of pooled data from two separate 
experiments performed under the same parameters using KO, F1 and F1xKO mice.  
Day two experiments were conducted on F1xKO mice. Day 4 experiments were 
conducted on KO and WT. Blood was taken at time of sacrifice to verify αGal 
expression.  
5.4 WT B6 and GT KO infections with γMHV-68 
Similar to the herpes viruses tested previously, the gammaherpes virus, γMHV-68 
replicated to higher levels in cells negative for GT expression.  In order to test for 
possible GT-dependent differences in susceptibility to infection in vivo, GT KO 
and WT B6 male mice aged 8-9 weeks, were inoculated i.p. with virus, and 
spleens were harvested at day 7 pi.  Titers from splenic suspensions (PFU/organ) 
were too low, or under the limit of detection, to be analyzed by plaque assay.  
However, in mice, after virus is cleared from circulation (acute infection), γMHV-
68 establishes a latent infection in B cells of the spleen that can result in 
splenomegaly (Sunil-Chandra et al., 1992).  By macroscopic examination, 
relatively larger spleens were observed from GT KO mice compared to spleens 
from WT mice at 7 days pi (Figure 22). 
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Figure 22: γMHV-68 infection on KO and WT mice.  Mice aged 9 weeks were 
inoculated i.p. with 5.5x103 PFU.  Spleens were harvested at day 7 for viral titration.  
Using the Adobe Photoshop CS6 Rule Tool, a scale was calibrated using the 
standard provided by the program, and an arbitrary unit (a.u.) of measurement was 
constant throughout the scale.  Spleen length according to this scale is written below 
each organ.  The majority of spleens harvested from GT KO mice exhibited 
increased size relative to the spleen from an uninfected control.  All spleens 
harvested from WT B6 were comparable in size, or smaller, to spleens from the 
uninfected mouse. 
γMHV-68-infected GT-negative mice exhibited splenomegaly to a greater degree 
than GT-positive mice.  In order to quantify infection, real-time PCR analysis was 
used to detect viral DNA present in infected GT-positive and GT-negative mice.  
Mice aged 6-12 weeks were inoculated i.p. with γMHV-68 and spleens were 
harvested at various days pi.  As with in vitro experiments, absolute quantification 
of viral copy number was not possible because no calibration standard was readily 
available.  Relative quantity of DNA was measured using an endogenous control; 
for each experiment, the sample with the lowest quantity of viral DNA was used 
as a standard to compare with the rest of the samples.  The unit of measurement, 
“fold change”, refers to a fold difference in quantity of DNA to the standard 
sample.  At 5 days pi, all GT-negative mice exhibited similar levels of viral DNA, 
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but a few GT-positive mice had 100’s to 1000’s-fold more DNA per gram in 
splenic samples relative to the standard (Figure 23a).  By day 7 pi, the majority of 
mice from both groups expressed levels of viral DNA close to the standard.   
At day 9 pi, the weight of individual spleens was also collected to see if size 
correlated with the level of viral DNA expression.  The average weight of a 
healthy mouse spleen is between 80-140 mg.  Gal-negative mice had spleen 
weights ranging from 130-340 mg, while Gal-positive individuals had spleen 
weights ranging from 90-140mg (Figure 23b).  PCR results confirmed that the 
larger spleens derived from Gal-negative mice.  These spleens also contained 
relatively higher amounts of viral DNA per gram compared to spleens from GT-
positive mice.  By day 11, both mouse types expressed relatively similar levels of 
viral DNA (Figure 23c).  Weights of spleens from GT-negative mice ranged from 
120-270 mg and for GT-positive mice, 100-390 mg.  Size of spleen again 
correlates with the relative amount of viral DNA present in the organ.  Data are 
inconclusive for GT-dependent differential susceptibility to γMHV-68 infection.  
At day 7 and 9 pi, GT-deficient mice have higher concentration of γMHV-68 
virus in spleens, and greater splenomegaly, compared to GT-sufficient mice.  But 
this is likely not true at day 5 and day 11 pi.  Working in relative quantities for 
viral load makes it difficult to fully understand kinetics differences of γMHV-68 
infections in the two mouse strains.  More work with a calibration standard would 
greatly elucidate the dynamics of viral infection between the two mouse types.  

 
Figure 23: γMHV-68 infection on KO, WT and backcrossed mice.  Mice aged 
between 6-12 weeks were inoculated i.p. with 3.5x103 PFU (Day 5, 9 and 11 pi) or 
5.5x103 PFU (Day 7).  Spleen was harvested at various days pi for real-time PCR 
analysis.  (A) Spleens from 12-wk old mice harvested at day 5 pi, and spleens from 9 
week old mice harvested at day 7 pi (B) Spleens from 11 week old mice were 
harvested and weighed at day 9 pi (C) Spleens from 6 week old mice were harvested 
and weighed at day 11 pi.  
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5.5 Adult WT and KO mice are equally permissive to SINV S.A.A.R86 
infection 
Findings from cell culture experiments indicated that SIN viruses preferentially 
replicated in cells with an active GT gene, and it was important to confirm these 
findings in an animal system.  Most strains of SINV are avirulent in adult and 
suckling mice.  After approximately 2 weeks of age, mice can control infections 
via an IFNα/β response, but for neonates that lack a functional IFN response (up 
to 14 days of age), most SINV strains induce a severe, lethal viral encephalitis 
(Reinarz et al., 1971; Ryman et al., 2000).  Adult and suckling mice, however, are 
susceptible to the neuroadapted S.A.A.R86 strain (Russell et al., 1989; Heise et 
al., 2000; Ryman et al., 2000).  To test for differences in susceptibility of KO and 
WT mice to S.A.AR86, 8 to 9 week old male mice were inoculated i.p. with the 
virus.  From the i.p. route, the virus infects skin, muscle, and various visceral 
organs and disseminates to the CNS via a viremia.  Mice were sacrificed by 
cervical dislocation, and blood, spleen, visceral fat pads or brain were harvested 
from day 1 to 5 pi.  Additionally, a group of mice was γ-irradiated to examine the 
response of immunocompromised KO and WT mice to infection.  Organs from 
irradiated mice were harvested at day 6 pi and titrated for virus.  At days 1 and 2 
pi, mean viral titers from organ suspensions of blood, spleen and fat pad were 
comparable between KO and WT mice (Figure 24a and 24b).  At day 3, more 
virus was found in the spleens of WT mice than KO mice, but the difference was 
not statistically significant (Figure 24c).  By day 5 pi, the virus was detected in 
the brains of both KO and WT mice at comparable levels (Figure 24d).  In 
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irradiated mice, at day 6 pi, no statistically significant difference in viral growth 
in blood, spleen (Figure 24e), liver and fat pad (not shown) was observed between 
GT-positive and GT-negative mice.  These results indicate that adult WT and KO 
mice are comparably susceptible to the virulent SINV S.A.AR86 strain. 
Figure 24: S.A.A.R86 infections of WT and KO mice.  Mice aged 8-9 weeks were 
inoculated i.p. with 105 PFU in 200 μl.  Blood, spleen, fat pads, or brain was 
harvested at days 1, 2, 3 and 5.  A second group of 8 week old mice was γ-irradiated 
with 10Gy and inoculated with the same dose of virus.  Blood, spleen, liver and fat 
pad were harvested at day 6 pi. (A) Day 1 results are representative of pooled data 
from two separate experiments performed under the same parameters (B) Day 2 
results from blood, spleen and fat pad are also from pooled data from two separate 
experiments (C) Only spleens were harvested for titration at day 3 pi (D) Only brain 
was harvested at day 5 pi for titration (F) Titers from blood and spleen of γ-
irradiated mice. 
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5.6 SINV infected WT suckling mice have accelerated symptom onset and 
death compared to KO counterparts 
In adult mice, no differences were observed in the response to SINV infection by 
GT-sufficient or GT-deficient mice.  However, very young mice are susceptible to 
most SINV strains and could provide clues about host-specific differences in 
response to infection.  In order to determine this, GT KO and B6 mice aged 6 to 
20 days were inoculated intracranially, because the virus is neurotropic, or 
subcutaneously, to mimic the natural route of vector-borne infection.  For these 
experiments I used the less virulent AR339 strain and the more virulent S.A.AR86 
strain.  I tested a variety of ages for infection and found that mice infected at day 
6 were not cared for by their mothers and that mice infected at day 20 were 
resistant to the lethal effect of either strain.  Infections of mice from 8 to14 days 
of age resulted in 100% mortality, regardless of the presence or absence of αGT.  
However, significant differences were observed in mean survival period prior to 
death and onset of pathological symptoms.  Intracranial infections of 8-day old 
mice with the more virulent SINV S.A.AR86 resulted in a rapid onset of 
spasmodic behavior and lethargy.  All WT mice died by day 3 and a few KO mice 
survived until day 4, but this difference was not statistically significantly.  Figure 
26 shows an experiment where 8-day old WT mice infected i.c. with SINV 
AR339 had a shorter mean survival time than KO mice (3.0 vs. 4.0 days).  WT 
mice exhibited spasms and trembling, unsteady locomotion as early as 24 h after 
inoculation and succumbed to infection beginning at 2 days post infection (Figure 
25).  In contrast, KO mice experienced morbidity around day 2 and 3 and began 
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dying at day 4.  Thirteen day-old KO mice inoculated subcutaneously with 
S.A.AR86 had a longer mean survival time compared to WT mice (5.0 vs. 4.0 
days) and experienced weight loss later than WT mice (day 3 vs. day 2).  Shaking 
and hind limb paralysis were observed by day 2 in WT mice and on day 4 in GT 
KOs.  At fourteen days of age, both KO and WT mice began dying on day 4 pi 
and survived until day 6 pi, and showed no significant differences in survival 
times and symptomology.  These data reflect the same pattern of susceptibility to 
SINV seen with cultured cells.  Altogether, these data show that GT-sufficient 
suckling mice have increased sensitivity to the lethal effects of SINV compared to 
GT KO counterparts.  GT KO mice eventually succumb to infection, but the onset 
of pathological symptoms and death are significantly delayed.   
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Figure 25: SINV infections of KO and WT weanling mice. A) Eight-day old mice 
were inoculated intra-cranially with approximately 200 pfu SINV HR strain in 10 μl 
of media (2 litters KO n=15, 2 litters WT n=13) or (B) 13-day old mice were 
inoculated subcutaneously with approximately 1.68x103  PFU of SINV S.A.AR86 in 
30μl (3 litters KO n=17, 2 litters WT n=10). 
To determine if differences in survival time and disease progression in GT-
sufficient and GT-deficient suckling mice correlate with differences in viral 
replication in the brain, eight-day old mice were infected i.c. with either a high 
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dose (1.16x106) or low dose (200  PFU) of SINV AR339.  With a high dose of 
virus, the effects of an abundant infection can be observed, as a high number of 
cells should be infected.  With a low dose, the ability of a virus to replicate within 
the host can be observed, as few cells should be initially infected.  The F1xB6 
generation of mice was used in lieu of WT to represent a GT-sufficient host 
because these mice were readily available and age matched to the KOs.  This 
group was given the high dose.  For the low dose experiment, age-matched GT-
sufficient and GT-deficient counterparts were not available, but a litter of F1xKO 
mice was.  Each mouse had a 50% chance of either expressing or not expressing 
the GT gene; a mix of GT-expressing and GT non-expressing individuals in the 
group was likely.  These mice were used to compare viral replication in the brain 
from a lower dose of virus.  For high-dose and low-dose experiments, brains from 
KO and WT mice were harvested at 24 h pi and titrated for virus.  At 24 h pi, 
titers from brain suspensions of all three types of mice reached levels of up to 
6x108  PFU/mL, regardless of the initial inoculum, or possible genotype of the 
mouse (Figure 26).  These data suggest that viral replication is not curtailed in 
GT-deficient mice relative to GT-sufficient mice.  Delayed onset of disease and 
death in GT KO mice does not appear to be correlated with inhibition of viral 
replication in the brains of these mice.   
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Figure 26:  SINV AR339 infections of  KO and backcrossed mice.  Eight-day old GT 
KO and genetically crossed (F1xB6) mice were give a high dose of virus, 1.1x106
PFU.  F1xKO were inoculated with a lower dose of 200 PFU.  Brains were harvested 
24 h pi.
In vivo experiments have demonstrated that KO mice for the GT gene are more 
susceptible to HSV-2 infection compared to GT-sufficient mice.  This parallels 
the results from in vitro studies, which show that GT expression in a host cell 
decreases susceptibility to herpes virus infection.  Results from experiments using 
genetically crossed mice to verify the greater susceptibility of αGal-negative mice 
to HSV 1 and 2 were not as conclusive, and it is possible that a biological factor 
in the KO mice affects their response to infection, prior to being crossed with WT 
B6 mice.  However, results from these experiments are difficult to interpret 
because the true level αGal expression in individual mice was difficult to assess.  
Results from experiments with γMHV-68 to verify greater susceptibility in KO 
mice to other herpes viruses were also not consistent with in vitro findings.  More 
work with this virus is necesseary to verify results.  For Sindbis virus infections, 
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suckling mice that express the GGTA1 gene experience faster onset of 
pathological symptoms and death compared to GT-deficient mice.  This also 
parallels in vitro data where SINV shows greater infectivity in GT-positive hosts.  
Overall, in vivo data support my hypothesis that host susceptibility to different 
viral infections is dependent on the expression or non-expression of GGTA1 in the 
host. 
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CHAPTER 6 
DISCUSSION AND CONCLUSIONS 
 
The present study provides the first investigation on the infection dynamics of 
viruses in the presence and absence of the α1,3-galactosyltransferase (GGTA1) 
gene.  I have shown that the loss of GT expression rendered cells more resistant to 
several viruses belonging to the Sindbis group but more sensitive to various 
herpes viruses, regardless of αGal expression or non-expression on the infecting 
viruses.  Additionally, differences in efficiency of infection were seen with SINV 
and herpes viruses, but once productively infected, host cells generally expressed 
similar amounts of viral protein as indicated by GFP expression.  This points to a 
role for GT activity or a GT product early during the course of an infection.  At 
the organismic level, I have shown that SINV strains are more virulent to GT-
expressing young mice compared to GT-deficient suckling mice.  In contrast, 
adult WT mice infected with HSV-2 exhibited less pathology and lower viral 
replication compared to KO mice.  These findings demonstrate that the presence 
of the GT enzyme in a host can alter their susceptibility to viral infection.  This 
study also provides insight on the evolution of disease resistance in catarrhine 
primates.  The significance of a mutation that occurred approximately 28 Ma, that 
inactivated GGTA1, and modified the carbohydrate repertoire of the ancestors of 
catarrhine primates, is not fully understood.  Here, I provided evidence that this 
mutation had the capacity to significantly alter host resistance to viral infections, 
and I speculate that this change in resistance to infections may have provided a 
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selective advantage to individuals harboring the mutation.  In this study, SINV 
grew to 10-20 fold higher in GT-positive cells and caused more rapid death in 
GT-positive suckling mice.  Selection may have acted on the GT locus, directly 
altering host cell susceptibility to virulent infection.  However, the mechanism by 
which GT-dependent differential susceptibility to viruses operates still remains to 
be deciphered.  It is important to once again note that the viruses examined in this 
study would not have been the putative selection agents of 28 million years ago.  
While it may not be possible to identify the pathogenic agent that exerted 
selective pressure on the GT locus, it is possible to conjecture that loss of GT 
expression rendered ancestral catarrhines more resistant to a virus or other 
pathogens with the ability of modern day SINV strains to favorably replicate in 
GT-positive hosts.   
 
It is more difficult to explain how a mutation that enhanced susceptibility to some 
viruses, as was observed with contemporary strains of HSV, could also be 
advantageous to the host.  It is very possible that HSV evolved specificity for 
cells that did not express surface αGal after the mutation became fixed in the 
population.  For instance, selective pressure from Plasmodium reichenowi (Martin 
et al., 2005) likely led to loss of expression of the terminal sialic acid, Neu5Ac, a 
product of the CMAH gene, in the ancestral hominin lineage around 3 Ma 
(Orlandi et al., 1992; Chou et al., 1998; Hayakawa et al., 2001: Hayakawa et al., 
2006).  The inactivation of the CMAH gene presumably rendered humans less 
susceptible to malarial infections for some time until the Plasmodium parasite 
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evolved the ability to exploit the mutated site once again (Hayakawa et al., 2001; 
Rich et al., 2009).  Today, that domain is still under strong selective pressure from 
Plasmodium and other pathogens (Martin et al., 2005), clearly indicating that 
host-pathogen relationships are not static.  In a similar manner, inactivation of 
GGTA1 may have provided ancestors of catarrhines with temporary relief from a 
virulent pathogen that exerted pressure on that locus, but this would not have 
eliminated the ability of other (even related) pathogens to exploit hosts expressing 
ΔGGTA1.  It is also of interest that herpes virus infections can sometimes benefit 
the chronically infected host.  Recent work with mice has shown that herpes virus 
latency can induce a state of heightened NK cell activity that results in swifter 
action against new infections, and certain human herpesvirus infections may have 
similar properties (White et al., 2012).  Furthermore, the periodic activation of 
latent or persistent viruses can induce chronic IFN-γ secretion and macrophage 
activation that can provide cross protection against acute bacterial infections 
(Barton et al., 2007).  
 
The greater susceptibility of GT KO mice to HSV-2 compared to WT B6 mice 
was evident, but the greater susceptibility of crossed mice that expressed low 
levels of αGal compared to mice that expressed high levels of αGal, was much 
less clear.  Overall, GT-negative mice presented slightly higher viral titers and 
greater pathology than GT-positive mice, but the data were not as definitive as 
that obtained from infections with the parental strains of mice.  Additionally, 
infections of crossed mice with HSV-1 did not show differences in response to 
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virus between αGal expressors and non- or low expressors.  This could indicate 
that the susceptibility of GT KO mice may be due to a factor that is present in the 
mice prior to crossing with the WT, or alternately, increased resistance of crossed 
mice may be due to a factor that is present in the WT mice they are crossed with.  
In either scenario, the response would be independent of the GGTA1 gene or 
αGal.  It is important to note however, that interpreting results of experiments 
using the genetically crossed mice was made difficult because assessing the level 
of αGal expression in individual mice was problematic.  The expression of αGal 
was measured by BSl binding to Thy 1.2 cells derived from blood of gamma-
irradiated mice, but the small fraction of remaning Thy 1.2 cells post-irradiation 
may not be an accurate representation of αGal expression in the individual mice.  
More precise tests to assess genotype-phenotype associations, such as genetic 
tests, in addition to antibody binding tests of blood lymphocytes, would be highly 
useful in these experiments.  In this way, a better understanding of the correlation 
between homozygotes to an HSV response could be measured, in conjunction 
with a response to virus by heterozygotes that express varying levels of αGal on 
their cell surfaces. 
 
In cell culture, HSV-1 preferentially grew in cells that were GT-negative and this 
was not corroborated in vivo.  Wild type and KO mice showed no significant 
differences in HSV-1 titers from lung suspensions at various days post infection.  
αGal sites are found on all tissues (except sperm cells) of the body in GT-
sufficient species (Thall et al., 1995), but the level of expression on different 
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tissues can vary, as can the level of expression by individual.  Thus, the level of 
expression on the specific cell the virus infects may determine susceptibility of 
the entire host.  HSV-1 infections were performed intranasally, and αGal 
expression is abundant in the vomeronasal organ (Koike et al., 2007).  Variable 
expression of αGal at the site of inoculation may not explain the comparable 
levels of HSV-1 viral replication between WT and KO mice as measured from 
lung suspensions.  However, it is possible that route of infection and organs 
accessible for viral dissemination may influence the outcome of infection.  For 
example, i.p. inoculation of HSV-1 often results in subclinical infections barely 
detectable in visceral organs (Renis et al., 1976), but i.n. inoculation causes 
obvious disease in the lung.  It is possible that GT expression plays no role in 
HSV-1 infections in vivo, but it is important that other routes of infection (e.g., 
intracranial, corneal) that result in measurable infection, and the level of αGal 
expression in infected tissues, be tested in order to verify this possibility.   
 
Results from in vivo infections with γMHV-68 are not easy to interpret because of 
repeatability issues with these assays.  Titers derived from mice of the same 
genotype were highly variable, whereby some animals had quantities of virus 
many-fold higher than their littermates, and littermates would be expected to react 
similarly to infection.  A possibility is that the immune system interacts with the 
virus and influences the outcome of γMHV-68 infection in individual mice.  In 
addition, each experiment was completed once and therefore must be repeated 
with the same parameters to verify results.  Precise quantification of viral DNA 
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would also benefit these experiments.  Relative quantification of viral DNA was 
informative about differences in infection levels between individuals, but it was 
difficult to assess whether a relatively low amount of viral DNA indicated viral 
clearance or was simply the lowest measured quantity of very high levels of 
replication.  Two experiments did show that the majority of KO mice exhibited 
splenomegaly while WT mice presented spleens that were comparable in size to 
that of uninfected control mice.  This could indicate that more B cells are infected 
and accumulated in the spleens of KO mice compared to the WT, but additional 
experiments are necessary to clarify whether this observed difference is real. 
Fatality in suckling mice is associated with neuronal damage (Johnson, 1965; 
Tucker et al., 1993).  Interestingly, WT suckling mice succumbed to SINV 
infection and experienced disease significantly earlier than their KO counterparts, 
despite having similar viral titers in brain tissue.  One explanation for this is that 
viral replication within cells of both mouse types is comparable, but dissemination 
of the virus—and thus amount of tissue damage—is restricted.  Infections in cell 
culture showed that the susceptible GT-negative population was limited to a small 
subpopulation, and if this phenomenon translates in vivo, viral spread in brain 
tissue of KO mice may be slowed by the absence of GT expression.  As in cell 
culture, viral replication is not impeded in the mouse brains, but the extent of 
neuron involvement may be sufficiently limited to delay onset of disease 
symptoms and death.  Histology work of SIN GFP infected suckling mouse brains  
 
would elucidate this point.  Additionally, titration of other tissues from these mice 
would be informative regarding dissemination of the virus, and how extra-neural 
tissue involvement affects virulence. 
 
The possible mechanism by which expression of the GT gene alters the course of 
viral infections is by inhibiting the ability of a virus to initiate infection.  I 
hypothesized that αGal is involved in viral-host interactions during entry because 
αGal is a known active binding receptor to other pathogens, such as Clostridium 
difficile.  However, results from experiments to support my hypothesis have not 
been conclusive.  Fluorescence focus assays showed that GT-negative cells 
appeared to resist infection by SINV viruses, and even after long periods of 
incubation with virus and after several rounds of viral replication, a large fraction 
of cells remained uninfected.  The BL6 cell population likely represents a 
heterogeneous group in terms of their permissiveness to SINV infection that 
includes high- and low-permissive clones.  Previous work (Kim et al., 1993) with 
the MA-104 cell line, derived from monkey kidney cells, showed that upon 
infection with porcine reproductive and respiratory syndrome (PRRS) virus, cells 
produced low viral titers and monolayers showed focal cytopathic effects.  The 
parental MA-104 cell line yielded two subpopulations with different 
susceptibilities to PRRS infection, high- and low-permissive cell clones (Kim et 
al., 1993).  Infections on a different cell line, the PK15 porcine cell line, with the 
porcine circovirus type 2 (PCV2), demonstrated that only about 20% of the 
population was susceptible to infection (Zhu et al., 2007).  High- and low-
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permissive clones were also demonstrated in the porcine cell lines.  In SINV 
infection assays, BL6 cells showed similar characteristics to the parental MA-104 
and PK15 cell lines.  SINV-infected BL6 cells produced relatively low titers that 
appeared to derive from a fraction of the cell population, and monolayers 
exhibited focal cytopathic effects.  In contrast, SINV-infected BL6αGal cells 
yielded relatively high titers and monolayers were uniformly infected and lysed 
by virus infection.  If BL6 cells produce clones with differences in their 
susceptibility to SINV, it is important to identify the factor that permits 
propagation in permissive cells.  Perhaps results from experiments with α-
galactosidase can provide an explanation.  It can be argued that herpes virus 
infections on the BL6αGal cells may also exhibit a similar phenomenon as 
described above.  However, assays with HSV-1 GFP showed that infection on 
BL6αGal cells was almost negligible, indicating that, at least with HSV-1 GFP, 
the cells in the population were comparably non-permissive to infection. 
 
Enzymatic treatment of BL6 cells reduced infectivity of αGal-positive cells, 
possibly due to the loss of surface αGal.  However, this enzyme also further 
reduced the low level infectivity in αGal-negative cells that do not have a 
functional GT gene.  BL6 cells may still express low levels of terminal 
Galα1,3Gal residues via an additional glycosyltransferase, the iGb3S enzyme 
(Taylor et al., 2003; Milland et al., 2006).   iGb3S enzyme activity has been 
observed in rats (Taylor et al., 2003) and in GT KO mice and pigs (Milland et al., 
2006).  Our cell lines were consistently monitored for expression of αGal using 
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anti-Gal and BSl, but αGal was not detected in BL6 cells.  This may be because as 
shown in KO mice, detection by BS lectin or anti-Gal is poor as the αGal 
disaccharide expressed via iGb3S synthesis is restricted to glycolipids.  The sites 
in KO mice are recognized by monoclonal antibodies produced from GGTA-/- 
mouse splenocytes fused to NS-1 hybridoma cells (Milland et al., 2006).  BL6 
cells could potentially express barely detectable levels of iGb3S derived αGal 
residues, the presence (and removal) of which may have some effect on infection 
in these cells.  Alternatively, BL6 cells may express terminal galactose 
monosaccharides in variable amounts that may not be detectable by anti-Gal or 
BSl binding but are removed by enzymatic treatment.  The α-galactosidase 
enzyme has high specificity for terminal galactose substrates, which means the 
enzyme removes the terminal galactose from proteins that express the Galα1,3Gal 
structure, but it will also remove αGal residues from the surface of human red 
blood cells with the group B structure, Galα1,3Fuc (Zhu et al., 1996).  It is 
possible that while SINV may have greater affinity with the Gal-Gal linkage, 
resulting in a more productive infection of BL6αGal cells, the virus may also have 
some affinity for αGal monosaccharides.  SINV may infect BL6 cells that express 
certain levels of terminal galactose residues, the removal of which affects 
infectivity.  These observations should be further investigated. 
 
The involvement of αGal in the course of viral infections is thus an avenue that 
warrants further investigation.  Cellular glycans and host glycosylation pathways 
play an important role in viral infections (Reitter and Desrosiers, 1998; Varki and 
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Varki, 2007; Vigerust and Sheperd, 2007), and in this way the distribution of 
host-cell carbohydrates may even determine host range and tissue tropism 
(Schenider-Schaulies, 2000; Suzuki et al., 2000).  SIN viruses have widespread 
host repertoires and utilize the ubiquitously expressed protein NRAMP2 for 
binding and entry into host cells (Rose et al., 2011; Stiles et al., 2011).  It is 
unlikely that αGal would be a required receptor utilized in entry for SINV strains 
because loss of αGT expression limits, but does not completely inhibit viral 
infection.  Further, insect cells such as those of Aedes mosquitos, which SINV 
infects, lack terminal glycosylation from galactosyltransferases and 
sialyltransferases (Butters et al., 1981).  The most common terminal glycan 
expressed on SINV virions propagated in Aedes-derived cells is mannose (Hsieh 
et al., 1984).  On mammalian cells, αGal may instead participate in attachment or 
binding of SINV in a process analogous to how the virus may utilize heparan 
sulfate (Byrnes and Griffin, 1998); these receptors may promote initial adherence 
to host cells until higher affinity receptors are engaged (Schneider-Schaulies, 
2000).  Loss of heparan sulfate on host cells reduces SINV infection, but does not 
abrogate it.  HSV-1 and 2 entry into cells is a multi-step process initiated by viral 
glycoproteins binding to cellular heparan sulfate proteoglycans (WuDunn and 
Spear, 1989; Shieh et al., 1992; Shukla et al., 1999; Spear and Longnecker, 2003) 
followed by binding to entry receptors such as the herpesvirus entry mediator 
(HVEM) protein or nectin-1 and nectin-2 and includes other virion-cellular 
protein interactions (Whitbeck et al., 1997; Shukla et al., 1999; Spear and 
Longnecker, 2003).  Active expression of the αGT gene highly impairs infection 
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of both herpes virus strains.  Experimental blocking of viral glycoprotein 
interactions with cognate cellular proteins disrupted the entry processes and 
inhibited infection of HSV-1 (Whitbeck et al., 1997; Gianni et al., 2010).  It is  
conceivable that the presence of αGal on the cellular surface could somehow alter 
the interactions of binding or entry receptors and result in reduced infection 
efficiency for these herpesviruses. 
 
Pathogens are major drivers of evolution, but conservation work has shown it is 
often the case that synergistic causes are responsible for reducing the number of 
individuals in populations to the brink of extinction (Brook et al., 2008).  As such, 
climate change can influence ecosystems and animal biodiversity via altering 
pathogen or host biological processes (Harvell et al., 2002).  Recent studies on 
global climate change and infectious disease (Reiter, 2001; Harvell et al., 2002; 
Lafferty, 2009; Mills et al., 2010) have focused on the effects of warming 
climates on disease, likely due to the present-day warming phase, but it is 
conceivable that measurable climate change of any sort could affect the disease 
ecology of populations experiencing these changes.  The Oligocene was a period 
of vast climatic and geological change that also coincides with a great 
chronological gap in the primate paleontological record (Seiffert, 2007).  While 
the particular ecological conditions that basal catarrhines experienced in the 
Oligocene are not known, the world underwent climatic changes that affected 
animal habitats and the distribution of life on the planet.  In general, the fossil 
record shows a vast turnover of faunal species found at the Eocene-Oligocene 
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boundary and those present at the Oligocene-Miocene boundary (Seiffert, 2007; 
Kappelman et al., 2003).  For catarrhines, the scarcity of fossils that derive from 
the Oligocene makes it difficult to discern phylogenetic relationships between 
ancestral and descendant taxa, and to even estimate conclusive divergence dates 
for OWM and apes (Raaum et al., 2005; Steiper and Young, 2008; Perelman et 
al., 2011).  Numerous factors may have affected Oligocene primate evolution and 
lineage divergence.  GGTA1 inactivation around 28 Ma can inform us on timing 
of phylogenetic divergences; the work presented in this dissertation can inform us 
on one possible catalyst for lineage divergence in ancestral catarrhines.  
Pathogens with wide host-specificity can cause declines across sympatric 
populations and lineage divergence can result when less resistant populations 
within a species are culled (Van Blerkom, 2003).  In cases where genetic diversity 
is useful, polymorphism may be selected for in the population, such as with the 
major histocompatibility group of genes; however, specific alleles are favored 
when selection is directional (Van Blerkom, 2003).  In the case of the GGTA1 
gene, the mutated gene (ΔGGTA1) may have been favored if GGTA1 or its gene 
product could be exploited by a virulent pathogen.  Any factor that increases 
resistance to a pathogen or decreases infectivity of that pathogen is enough to 
increase fitness for an individual (Antonovics et al., 2013).  If the hypotheses 
tested during this research are correct, the loss of α1,3GT expression may have 
given αGal-negative catarrhines an advantage over αGal-positive catarrhines in 
controlling pathogens that could exploit the α1,3GT pathway without also 
stimulating an autoimmune response.  Additionally, the production of anti-Gal 
 
antibodies would have further protected GT-negative species from zoonotic 
transmission.  Viruses can shape the evolutionary trajectory of the organisms they 
infect, as well those that the infected organisms are in contact with.  Experimental 
evidence on the significance of α1,3GT activity and αGal expression in viral 
disease such as that presented here may shed light on the processes that helped 
shape catarrhine evolution during the Oligocene epoch. 
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APPENDIX 
LIST OF ABBREVIATIONS 
 
αGal   α1,3galactosyl 
α1,3GT or GT α1,3galactosyltransferase 
ΔGGTA1  mutated ( !" $)( #($"#"#,
γMHV-68   murine gammaherpes virus 68 
ab   antibody 
ANOVA  analysis of variance 
APC   allophycocyanin 
BSl-B4 or BSl  lectin from Bandeiraea simplicifolia 
CCR5   leukocyte chemokine (C-C motif) receptor 5
cDNA   complementary DNA 
CHIK    Chikungunya virus 
CMAH   cytidine monophosphate-N-acetylneuraminic acid   
   hydroxylase 
CMP    cytidine monophosphate
   $""& %##(#$
!   (#! #$$ 

!"$  $&$""!"$
   $(#% '
   !#$+""&"%#
FACS    fluorescence-activated cell sorting 
FBS   fetal bovine serum 
FCS   fetal calf serum 
FITC   fluorescein isothiocyanate 
FSL   functional spacer lipid construct 
GFP   green fluorescent protein
  ( !" $)( #($"#"#,
 "  GGTA1  %$
Gy   gray unit 
GYPA   glycoprotein A
!    %"#! #$$ 
	   haemagglutin
HIV   human immunodeficiency virus
	+,   "!##!'&"%#$(!,
	+-   "!##!'&"%#$(!-
**   $""
**   $"#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 **,
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    " (  
PBS   phosphate buffered saline 
PCR   polymerase chain reaction  
PFU   plaque forming units 
pi   post infection 
PPG   processed pseudogene
PV   Pichinde virus 
R-PE   R-phycoerythrin
   "  
   $""
#))   #%%$ %#
   #&"%#
    "#$&"%#
ST6GAL1  ST6 beta-galactosamide alpha 2,6-sialiyltranferase 1
UMMS  University of Massachusetts Medical School 
UPG    unprocessed pseudogene 
VSV   vesicular stomatitis virus 
VZV   varicella-zoster virus 
WEE   Western equine encephalitis virus 
WNV   #$&"%#
   '$(!
+  '$(!C57BL/6J 
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